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ABSTRACT

Leveraging Antibodies for Positron Emission Tomography and NearInfrared Fluorescence Imaging of Cancer
by
Kimberly Carol Fung
Advisor: Brian M. Zeglis

The high specificity and affinity of antibodies make them attractive for developing drugs to
diagnose and treat cancer. The overarching goal of this work is to explore the synthesis and use of
antibody-based imaging agents in preclinical models of cancer. This work can be described as twofold. In the first part, we investigated how the use of a glycans-specific bioconjugation strategy
affects FcRI binding and why it results in improved in vivo performance of immunoconjugates.
To do so, we used the clinically relevant positron emission tomography (PET) imaging agent, 89ZrDFO-Pertuzumab, in mouse models of human breast cancer. In the second part, we developed two
imaging agents for ovarian cancer,

89 Zr-DFO-AR20.5

for PET and ssB43.13-IR800 for near-

infrared fluorescence imaging and evaluated their in vivo performance in mouse models of human
ovarian cancer. With this body of work, we hope to demonstrate the potential of antibodies as
effective imaging agents for cancer.
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Chapter 1 : Introduction
The unmatched ability of antibodies to specifically target disease-associated antigens makes
them desirable for developing drugs to diagnose, treat, and manage cancer.1-4 In recognizing the
clinical potential of antibodies for diagnostic imaging, research into antibody-based molecular
imaging agents has grown considerably over the past two decades, especially in oncology.2 Two
imaging modalities that have been studied extensively are positron emission tomography (PET)
and near-infrared fluorescence (NIRF) imaging. PET and NIRF imaging provide noninvasive ways
to visualize biochemical processes in vivo. PET is a highly sensitive and quantitative nuclear
imaging technique that enables whole-body imaging. NIRF imaging is a clinically relevant
technique that holds great promise for image-guided surgery. With these studies, our goal is to
leverage antibodies for PET and NIRF imaging in preclinical mouse models of cancer.
This body of work explores the synthesis and application of immunoconjugates for the
imaging of cancer. Chapter 2 investigates the effect of bioconjugation strategy on the FcyRI
receptor and the in vivo performance of the radioimmunoconjugate,

89Zr-DFO-Pertuzumab,

in a

human breast cancer mouse model. Chapters 3 and 4 explore the use of antibodies for imaging
ovarian cancer, which is the deadliest gynecological malignancy in the United States. Chapter 3
details the development of an immunoPET imaging agent for imaging mucin-1 (MUC1), which is
overexpressed in primary epithelial ovarian cancer and >90% of metastatic cancers. Chapter 4
details the development of a NIRF imaging agent that targets cancer antigen 125 (CA125), which
is overexpressed in high grade-serous ovarian cancer.
In this work, we hope to demonstrate that combining antibodies with PET and NIRF
imaging create powerful tools for diagnostic imaging and image-guided surgery of cancer. Of
course, the ultimate goal of this work is to translate these imaging agents into the clinic and support
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clinicians in the diagnosis, treatment, and management of cancer.
1.1. Molecular Imaging
Molecular imaging is a growing field that is valuable for diagnosing, monitoring, and
managing the treatment of disease, especially in the fields of oncology, cardiology, and neurology.
According to the Molecular Imaging Center of Excellence (MICoE) and Society of Nuclear
Medicine (SNM), molecular imaging is defined as “the visualization, characterization, and
measurement of biological processes at the molecular and cellular levels in humans and other living
systems”.5 Molecular imaging comprise the following imaging modalities: single photon emission
computed tomography (SPECT), positron emission tomography (PET), magnetic resonance
spectroscopy, optical imaging (bioluminescent and fluorescence imaging), molecular ultrasound
imaging, hybrid imaging (e.g. PET-CT, PET-MRI), and others.6, 7 Typically, an imaging agent is
used to perform molecular imaging. The imaging agent consists of a targeting moiety (e.g.
antibody, peptide, small molecule) that directs the agent to the molecule of interest and a signaling
moiety (e.g. radionuclide, fluorophore) that permits visualization of the agent.7 Once the imaging
agent has reached its target in the body, it can be imaged with the appropriate device and images
can be generated for clinical use.
The benefits of molecular imaging include its noninvasive nature and ability to detect
disease at earlier stages. To diagnose diseases, more invasive procedures such as biopsy or surgery
are often necessary. Molecular imaging offers a noninvasive way to detect chemical and biological
processes that indicate the occurrence and progression of disease. Other clinically employed
imaging modalities such as x-rays, computed tomography (CT), and ultrasound primarily provide
anatomical information. However, it would take more time before the disease can be detected with
these modalities because the disease would have to progress to a stage where it is anatomically
visible.7, 8 Lastly, molecular imaging modalities can be coupled with structural imaging modalities,
2

such as CT or MRI to obtain both anatomical and biochemical information.
For the purpose of this work, I will focus my discussion on the imaging modalities, PET
and NIRF. The features of select imaging modalities are presented in Table 1.1. PET is a highly
sensitive, whole-body imaging technique that is widely used in the clinic. It has an excellent depth
of penetration and provides quantitative data. A drawback of PET is that it requires the use of
ionizing radiation (i.e. radiation with enough energy to remove electrons from atoms or molecules),
which can damage tissues with high levels of exposure. Other limitations are that it is relatively
expensive and mostly requires the use of radionuclides that can only be generated via a cyclotron.
NIRF imaging falls under the category of optical fluorescence imaging. Optical fluorescence
imaging is a relatively inexpensive imaging technique that does not require the use of ionizing
radiation and allows for the imaging of multiple agents in one session. It is generally safe for use
in clinical studies, but it is dependent on the fluorophore used and the mass required for imaging
(typically exceeds that required for PET or SPECT). The limitations of fluorescence imaging are
the limited depth of penetration, surface weighting issues (i.e., objects closer to the surface appear
brighter), and autofluorescence, which compromises the sensitivity of the technique. The use of a
near-infrared imaging agent can help remedy some of these issues (will be discussed in the
following section) as well as type of imaging instrument used and corrections applied.
Modality
Computed
tomography
(CT)
Magnetic
resonance
imaging (MRI)
Positron
emission
tomography
(PET)

Spatial
Resolution
50-200 µm
(preclinical)
0.5-1 mm
(clinical)
25-100 µm
(preclinical)
~1 mm
(clinical)
1-2 mm
(preclinical)
5-7 mm
(clinical)

Depth of
Penetration
Limitless

Sensitivity

Cost

Safety Profile

Not determined

$$

Ionizing radiation

Limitless

10-3 to 10-5 M

$$$

No ionizing radiation

Limitless

10-11 to 10-12 M

$$$

Ionizing radiation

3

Single photon
emission
tomography
(SPECT)
Ultrasound (US)

Optical
fluorescence
imaging

1-2 mm
(preclinical)
8-10 mm
(clinical)
0.01-0.1 mm
for
superficial
(few mm
depth)
applications
1-2 mm for
deeper (few
cm depth)
applications
2-3 mm

Limitless

10-10 to 10-11 M

$$

Ionizing radiation

mm-cm

Excellent when
microbubbles are
used (~10-12 M)

$

Good safety profile

<1 cm

~10-9 to ~10-12 M

$

3-5 mm

1-2 cm

~10-15 to 10-17 M

$

Good safety profile
but depends on
fluorophore used and
mass
Good safety profile

Optical
bioluminescence
imaging

Table 1.1. Features of select molecular imaging modalities.7
1.1.1. PET Imaging
1.1.1.1. Principles of PET Imaging
Positron emission tomography (PET) is a highly sensitive, quantitative imaging technique
with a multitude of clinical applications. PET requires the use of a positron emitter, which is a
radionuclide that decays through the emission of a positron (β+). The nucleus of a positron emitter
contains an excess of protons, causing instability. To regain stability, a proton in the nucleus is
converted to a neutron and a positron along with a neutrino.7
During a PET scan, a positron-emitting imaging agent is administered to the subject,
allowed to accumulate at the target site (e.g., tumor), and a positron is emitted from its nucleus
(Figure 1.1). As the positron passes through tissue, it quickly loses kinetic energy, collides with an
electron, and they mutually annihilate. The annihilation produces two coincident 511 keV photons
(the rest-masses of the positron and electron are converted to their energy equivalent) that travel in
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opposite directions. The two coincident photons exit the body and register on a ring of scintillation
detectors surrounding the subject.9, 10 When both photons are detected simultaneously by two
opposing detectors (typically within 4 to 12 ns), it is recorded as a coincidence event.11 Since the
photons are approximately 180° apart, this places the coincidence event along the volume between
the opposing detectors, referred to as the line of response. Throughout the course of a PET scan,
many coincidence events are recorded, allowing for localization of the radionuclide to a location.
The data are then corrected for photon attenuation, scatter, accidental coincidence events, detector
dead time, detector efficiency and ultimately reconstructed into 3D images. For preclinical studies,
the same principles apply, but a small animal PET scanner is used (refer to Table 1.1 for
properties).7, 9, 10

Figure 1.1. Principle of positron emission tomography (PET). Created with BioRender.com.
It is important to note that PET cannot be used to image multiple radionuclides in one scan.
A PET scanner only detects photons of a single energy because regardless of the positron emitter,
only 511 keV photons are emitted during the annihilation event. On the other hand, single photon
5

emission computed tomography (SPECT) can distinguish between the radionuclides based on their
emission energies.10 All factors considered, PET offers several advantages over SPECT such as
higher sensitivity and spatial resolution (refer to Table 1.1 for values).12
1.1.1.2. Positron Emitters
Radionuclide

Half-life (t1/2)

Eß+ (keV)

11C
15O

20.4 m
9.97 m
2.04 m

385.6
491.82
735.28

Decay mode (%
branching ratio)
ß+ (100)
ß+ (100)
ß+ (100)

18F

109.77 m

249.8

ß+ (100)

124I

4.18 d

64Cu

12.7 h

687.04,
974.74
278.21

68Ga

67.71 m

836.02

86Y

14.74 h

535

89Zr

78.4 h

395.5

ε + ß+ (100)
ß+ (22.7)
ε + ß+ (61.5)
ß+ (17.6)
ß- (38.5)
ε + ß+ (100)
ß+ (89.14)
ε + ß+ (100)
ß+ (31.9)
ε + ß+ (100)
ß+ (22.74)

13N

Main production
routes
14N(p,ɑ)11C
16O(p,ɑ)13N
15N(p,n)15O
15N(d,n)15O
18O(p,n)18F
20Ne(d,ɑ)18F
124Te(p,n)124I
64Ni(p,n)64Cu

68Ge/68 Ga-generator
86Sr(p,n)86Y
89Y(p,n)89Zr

Table 1.2. Physical decay characteristics of the most commonly used PET radionuclides.12, 13
When selecting a positron emitter for preclinical and clinical studies, factors such as the
half-life, decay characteristics, production routes, and ease of synthesis should be considered. The
physical decay characteristics of the most commonly used PET radionuclides are presented in Table
1.2. The non-metallic positron emitters, 11C, 13N, 15O, 18F, and 124I, are typically used with small
molecule tracers with rapid pharmacokinetics. With the exception of 124I, they all have short-half
lives that are only suitable for investigating biochemical processes over a short period of time,
typically minutes or hours at most. Due to their half-lives, use of these radionuclides often requires
the presence of a local medical cyclotron. In addition, they typically have to be incorporated into
the tracer itself, which can result in complicated and long syntheses. Most of the radiometals, 64Cu,
6

86Y,

and 89Zr, have longer half-lives, which are suitable for conjugation to bimolecular targeting

moieties such as antibodies and peptides. By using bifunctional chelators that bind the radionuclide,
they can easily be appended to these biomolecules.12 For our studies, we chose to use 89Zr because
its physical half-life of ~3.3 days is a close match to the biological half-life of antibodies (Table
1.2). It also has a lower energy positron than most of the other commonly used radionuclides, which
translates to a higher spatial resolution in the PET image.
1.1.2. Fluorescence Imaging
1.1.2.1. Principles of Fluorescence Imaging
Fluorescence imaging relies on the use of a fluorophore, a molecule capable of absorbing
and re-emitting light. The general process of fluorescence imaging is illustrated in Figure 1.1. First,
light is filtered to the appropriate wavelength for exciting the fluorophore. The fluorophore can be
either a biological molecule located in the tissue (i.e., autofluorescence) or an administered
fluorophore. The light must then pass through the tissue to reach the fluorophore. The fluorophore
absorbs the photons and reaches an excited state. It remains in the excited state for a very short
amount of time, usually a few nanoseconds, depending on the lifetime of the fluorophore. When it
returns to its ground state, it emits photons. During the transition between the two states, energy is
lost and a shift to longer wavelengths (lower energy) – referred to as the Stokes shift – occurs.
Lastly, only a small portion of the emitted light can be detected with a charged coupled device
(CCD) camera, which converts light into electrons and generates an image.14
Not all of the emitted light will reach the camera because when light travels through the
tissue, the following processes occur: reflection at the tissue surface, absorption, scattering, and
autofluorescence.15, 16 First, the difference between the refractive indices of air (n ~1.0) and tissue
(n ~ 1.4) causes some of the excitation light to be reflected at the tissue surface.16, 17 Second,
components within the tissue – primarily water, lipids, oxygenated hemoglobin, and deoxygenated
7

hemoglobin – can absorb light. At wavelengths below 650 nm, oxyhemoglobin and
deoxyhemoglobin absorb a great deal of light, which limits the depth of light penetration into the
tissue (Figures 1.2A and B). Above 900 nm, water absorbs light (Figure 1.2A).15 Third, photons
can change directions when traveling through tissue, an effect referred to as scattering. As the
wavelength increases, scattering is reduced in all types of tissue. Lastly, in the ultraviolet and
visible light region (200-700 nm), endogenous fluorophores in the tissue such as reduced
nicotinamide adenine dinucleotide (NADH) and flavins can absorb light and result in
autofluorescence.14,

16, 18

In fluorescence imaging, it is important to maximize the tumor-to-

background ratio (referred to as the signal-to-noise ratio for general imaging purposes) because it
allows for proper differentiation between tumor and non-target tissues.14 Autofluorescence results
in nonspecific background signal, which decreases the signal-to-noise ratio and hampers one’s
ability to clearly visualize the target. Near-infrared (NIR, 700 – 1000 nm) fluorescence imaging
takes advantage of the window between 650-900 nm where there is limited interference from
autofluorescence and deeper tissue penetration.14, 15

Figure 1.2. Geometric and basic principle of fluorescence imaging. (A) Light of the appropriate
excitation wavelength is selected using a filter (Fex), which is located between a light source and
the tissue. The excitation light travels through the tissue and is absorbed by a fluorophore, which
subsequently emits light of a different wavelength. A small portion of this emitted light will exit
8

the tissue and can be detected with a camera. A filter (Fem) is placed in front of the camera, which
allows only the emitted light to pass into the camera. (B) Absorbed light by the fluorophore
instigates an electron (e) in the ground state toward an electronically excited state. Upon return to
the ground state, the fluorophore emits a photon. The wavelength of this emitted photon is specific
for the fluorophore. Fex, excitation filter; Fem, emission filter. Reprinted from Clinical Cancer
Research, ©2013, 19, 3745-3754, Keereweer, S. et al., Optical Image-Guided Cancer Surgery:
Challenges and Limitations, with permission from AACR.

Figure 1.3. Absorption of light. (A) Absorption of light by various components varies over the
wavelength spectrum, resulting in an optimal window for fluorescence imaging in the NIR light
region between 650 and 900 nm; (B) Penetration of light range from 0.5 mm to more than 10 mm
contingent to the wavelength. OxyHb, oxygenated hemoglobin; DeoxyHb, deoxygenated
hemoglobin. Reprinted from Clinical Cancer Research, ©2013, 19, 3745-3754, Keereweer, S. et
al., Optical Image-Guided Cancer Surgery: Challenges and Limitations, with permission from
AACR.
1.1.2.2. Fluorophores
Fluorophores are compounds, typically polyaromatic hydrocarbons or heterocycles, that are
capable of absorbing and re-emitting light upon excitation. As mentioned before, fluorophores in
the near-infrared (NIR) region exhibit the best properties for in vivo imaging because the effects of
absorption, scattering, and autofluorescence are greatly reduced in this region. In addition, the
following properties should be considered when selecting a suitable fluorophore for imaging:
solubility, photophysical properties, photostability, non-specific binding, clearance, and toxicity.189

20

Fluorophores should exhibit good solubility in aqueous solutions for administration in vivo. In

terms of photophysical properties, fluorophores should possess high brightness, quantum yields,
and extinction coefficients. The fluorescence quantum yield is defined as the number of photons
emitted per excitation photon absorbed and is measure of how efficient the process of fluorescence
is. Ideally, the quantum yield would be 100%, which means that every photon absorbed results in
the emission of a photon. The extinction coefficient is a measure of the capacity of the fluorophore
to absorb light at a particular wavelength. In terms of photostability, the fluorophore needs to retain
its photophysical properties in vivo. A major threat to photostability is photobleaching, which is
the photochemical destruction of the fluorophore (likely due to the generation of reactive oxygen
species). After repeated exposure to the excitation light, the excited fluorophore can become
unstable and permanently lose its ability to fluoresce. The fluorophore should have low binding to
non-target tissues, which could result in background signal. Lastly, the fluorophore should clear
quickly from the body and be nontoxic in vivo.18-20 All of these properties should be considered to
maximize the tumor-to-background ratio during imaging.
A brief list of NIR fluorophores that are FDA-approved or used in clinical trials is presented
in Table 1.3. In 1959, indocyanine green (ICG) became the first FDA-approved NIR fluorophore
for in-human clinical use. ICG is negatively charged, and thus, binds to proteins in plasma, such as
albumin, immediately after administration. The binding of ICG with plasma proteins causes
retention within the vascular system, which makes it well-suited for cardiovascular and lymphatic
angiography.14,

18, 20

ICG is rapidly cleared through the hepatobiliary system, which permits

imaging of the liver and bile duct.14, 16, 20 ICG also has applications in oncology such as detection
of the sentinel lymph nodes, liver metastases, hepatocellular carcinoma, and other cancers in imageguided surgery.16,

18, 20-26

Methylene blue (MB) is also FDA-approved, but the FDA issued a

warning against its clinical use in 2011, owing to reports of serotonin syndrome.16 MB emits in the
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far-red region (peak emission = 686 nm). It is positively charged, resulting in non-specific binding
to proteins. It is cleared through both the renal and hepatobiliary system with a third in the urine.
In the presence of a reducing agent, the central nitrogen atom of MB loses its aromaticity and as
result, its fluorescence; MB is thus converted to leucomethylene blue.16, 20, 21 MB has been used for
cardiovascular and lymphatic angiography; bile duct, gastrointestinal tract, and ureter imaging; and
image-guided surgery of parathyroid adenoma.16, 20, 21, 27-30 Though they are clinically relevant, ICG
and MB can only target tissues passively either through non-specific binding or the enhanced
permeability and retention (EPR) effect (for tumor targeting); neither can be conjugated to a
targeting moiety.
Two fluorophores, IRDye800CW and ZW800-1, are being tested in clinical trials.
IRDye800CW is a negatively charged dye that exhibits good solubility in water due to the
possession four sulfonate groups. Due to its low molecular weight and stability in serum, it is
quickly cleared through the renal system. Renal clearance is preferred over hepatobiliary clearance
because it does not produce high background signal in the GI tract. 31 IRDye800CW is
commercially available and can be functionalized with an NHS ester or maleimide for conjugation
to a targeting vector. IR800DyeCW has been conjugated to antibodies and peptides for imaging
and image-guided surgery for a variety of cancers such as breast, head and neck, and rectal cancer.
A recent article by van Keulen et al. reports the use of panitumumab-IRDye800CW for imageguided surgery in 14 head and neck patients enrolled in clinical trial, NCT02415881. 32
Panitumumab targets the epidermal growth receptor factor, a glycoprotein expressed in various
types of cancer. NIRF imaging with panitumumab-IRDye800CW identified a close tumor margin
in one patient, secondary primary tumor outside of the planned surgical area in a second patient,
and residual disease in a third patient. This study thereby demonstrates the construct’s utility for
intraoperative decision making.32 In addition to panitumumab, IR800CW has also been conjugated
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to the vascular endothelial growth factor (VEGF)-targeting antibody, bevacizumab, and EGRFtargeting antibody, cetuximab for use in clinical trials evaluating the dosage, safety, and efficacy
of the constructs (NCT01508572, NCT01972373, NCT02129933, NCT02583568, NCT03134846,
NCT03384238, NCT02415881).16 ZW800-1 is a zwitterionic dye that also exhibits good solubility
in water and renal clearance. Due to its neutral net charge, it has very low non-specific tissue
binding, resulting in higher tumor-to-background ratio when compared to other charged NIR
fluorophores.33-35 In various studies, ZW800-1 was conjugated to the cyclic peptide, cRGD, which
targets integrin ɑvß3. Integrins are a family of cell surface receptors that promote the attachment of
cells to the extracellular matrix (ECM). Studies report that the expression levels of integrin ɑ vß3
increase with tumor cell invasion and metastasis as well as the formation of tumor vessels. It is also
overexpressed in nearly all solid tumors. cRGD and RGD has been studied extensively in the clinic
and used as targeting moieties for PET and SPECT imaging studies, so there has been interest in
developing an improved cRGD-based NIR agent for imaging and image-guided surgery of
cancer.16, 20 In 2013, Choi et al. demonstrate that cRGD-ZW800-1 can be used to achieve higher
tumor-to-background ratios (17.2 ± 1.2) in mice bearing bilateral human melanoma cells (tumors
from ɑvß3-positive M21 cell line and ɑvß3-negative M21-L cell line) than conjugates with the NIR
fluorophores, IRDye800-CW (5.1 ± 1.2) and Cy5.5 (2.7 ± 1.4).34 Currently, there are two clinical
trials in the Netherlands using cRGD-IR800-1, one for squamous cell carcinoma of the oral cavity
and the other for colorectal carcinoma (Netherlands Trial Register number NL7724 and NL8049).
Many other NIR fluorophores are being tested in preclinical studies. 16 In addition, NIR
fluorophores emitting in the 1,000-1,700 nm range, referred to as NIR-II, have gained the interest
of researchers and are being developed and investigated for in vivo imaging.16
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Fluorophore

Excitation/
emission
wavelength
(nm)
807/822

Properties

Methylene
Blue (MB)

665/686

Positively
charged;
QY=9.6%
(serum)

IRDye800CW

774/789

Negatively
charged;
hydrophilic;
QY=12%
(serum)

Zwitterionic
cyanine dyes

772/788
(ZW800-1)

Zwitterionic
(neutral net
charge);
hydrophilic;
QY=15.1%
(serum)

Indocyanine
green (ICG)

Structure

Negatively
charged;
lipophilic;
QY=9.3%
(serum)
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Table 1.3. Structure, excitation/emission wavelength, and properties of clinically employed
fluorophores.16
1.2. Structure of Antibodies
Antibodies, also known as immunoglobulins, are glycoproteins that are produced by the
immune system. Antibodies have a Fab (Fragment antigen binding) region for binding its specific
antigen and a Fc (Fragment crystallizable) region for binding receptors on immune effector cells
(e.g. B cells, activated T cells). Each antibody contains a pair of identical light chains (L) and a
pair of identical heavy chains (H) that give the antibody its distinctive Y shape. The light chains
are ~25 kDa each and the heavy chains are ~55 kDa each. 36 These chains are held together by
interchain disulfide bonds and non-covalent interactions (i.e., hydrogen bonds, van der Waals
interactions) that vary based on the immunoglobulin isotype. The immunoglobulin G (IgG) isotype
consists of a total of 16 disulfide bonds, 4 of which are interchain disulfide bonds and 12 of which
are intrachain disulfide bonds.36, 37 For the purpose of this work, use of the term, “antibodies” will
refer to the IgG isotype (Figure 1.4). The light and heavy chains are composed of regions referred
to as the variable (V) and constant (C) domains. The light chain has one variable (V L) and one
constant domain (CL). The heavy chain has one variable domain (VH) and three constant domains
(CH1, CH2, CH3). The variable domains have three hypervariable complementarity determining
regions (CDR1, CDR2, CDR3) that are responsible for the antibody’s ability to recognize specific
antigens. The 2 Fab regions of the antibody are made up of the V L, CL, VH, and CH1 domains, and
the Fc region of the antibody is made up of the CH2 and CH3 domains. The Fab and Fc regions are
linked by a flexible hinge region that allows the two Fab fragments to move independently. 36
Lastly, it is important to note that the Fc region contains two conserved N-linked glycosylation
sites at the Asn297 residues, which has important implications for protein folding and interactions
with immune effector cells.36, 38
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Figure 1.4. Detailed structural schematic of a full-length IgG. Reprinted from ref. 36 under the
terms
of
the
Creative
Commons
Attribution
International
License
(http://creativecommons.org/licenses/by/4.0/).
1.3. Bioconjugation Strategies
1.3.1. Traditional Conjugation Method
The traditional conjugation method usually involves conjugating an amine-reactive chelator
or fluorophore to the lysines of an antibody (reaction shown in Figure 1.5). However, antibodies
possess a vast number of lysine residues, resulting in poorly defined and heterogenous constructs.
The benefits of this approach are that it is easily accessible and facile. On the other hand, it can
result in a possible loss of immunoreactivity if the conjugation occurs in the Fab region, and there
is heterogeneity at three levels.37, 39 First, the conjugation reaction will produce immunoconjugates
with different degrees of labeling (DOL). Second, regioisomers are likely to exist. Lastly, every
conjugation is different, so it is unlikely to produce batches with the exact same DOLs and mixture
of regioisomers.37
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Figure 1.5. Two most common types of bioconjugation reactions: Top, reaction of a primary
amine with a N-hydroxysuccinimide ester (NHS ester); Bottom, reaction of a primary amine and
isothiocyanate (NCS).
1.3.2. Site-specific Conjugation Method
Site-specific conjugation methods have been shown to produce more homogeneous, betterdefined, and more reproducible constructs than those synthesized with the traditional conjugation
method.40-45 Moreover, several studies have demonstrated that site-specifically modified
immunoconjugates exhibit improved in vivo behavior compared with randomly modified
constructs.46-51 Four main strategies for site-specifically modifying antibodies have been described
in the literature.37, 52 The first strategy incorporates peptide tags into antibodies. Peptide tags either
serve as recognition sites for enzyme-mediated conjugation or as the coordination framework for
radiometal chelation. The second strategy incorporates non-canonical amino acids into the antibody
via genetic engineering. The third approach utilizes cysteine residues to conjugate bifunctional
chelators to the antibody. While more accessible than the two aforementioned approaches, there
are still several cysteines located on the antibody, though fewer than the number of lysines. As a
result, antibodies modified in this manner may still have different degrees of labeling. The last
strategy relies on modifying the heavy chain glycans in the Fc region of the antibody (see structure
in Figure 1.6). A major advantage of modifying the glycans is that the distance between the Fc and
Fab regions of the antibody reduces the risk that conjugations will inadvertently occur in the
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antigen-binding regions. Additionally, the heavy chain glycans possess a biantennary
oligosaccharide chain, which allows for up to 4 conjugations per antibody. Lastly, this strategy
provides us with an accessible and modular way to produce site-specific constructs without
utilizing genetic engineering because the chemistry of sugars varies from that of amino acids.37, 40

Figure 1.6. (A) The biantennary structure of the heavy chain glycans; the dotted outlines indicate
residues that are not always present in the glycans. (B) Structures of natural and synthetic
monosaccharides. Reprinted from ref. 36 under the terms of the Creative Commons Attribution
International License (http://creativecommons.org/licenses/by/4.0/).
For the purpose of this work, we will focus on the glycan-based conjugation method. There
are two main methods for site-specific conjugation on the glycans: oxidation-based and
glycoengineering. In the oxidation-based method, the heavy chain glycans are oxidized with
periodate (IO4-) to produce aldehydes, allowing for selective reactions with nucleophiles. While
facile, this method may require reduction to obtain stable immunoconjugates and possibly result in
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the oxidation of methionine residues. In the glycoengineering method, natural and engineered
enzymes are used to incorporate modified sugars into the antibody in a chemoselective fashion.
The galactosyltransferase enzyme, Gal-T1(Y289L) is frequently used in this method because it
enables the transfer of azide-functionalized galactose residues. Bioorthogonal click chemistry,
particularly strain-promoted azide-alkyne cycloaddition (SPAAC), can then be used to incorporate
a variety of dibenzocyclooctyne (DBCO)-modified chelators and/or drugs into the antibody
construct (Figure 1.7).37, 46, 47

Figure 1.7. Schematic of a Gal-T(Y289L)-based site-specific modification procedure. Reprinted
from ref. 36 under the terms of the Creative Commons Attribution International License
(http://creativecommons.org/licenses/by/4.0/).
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Chapter 2 : The Influence of Glycans-Specific Bioconjugation on the
FcɣRI Binding and In Vivo Performance of 89Zr-DFO-Pertuzumab
This chapter is an adaptation of accepted work from Vivier, D.; Fung, K.; Rodriguez, C.; Adumeau,
P.; Ulaner, G. A.; Lewis, J. S.; Sharma, S. K.; Zeglis, B. M. The influence of glycans-specific
bioconjugation on the FcɣRI binding and in vivo performance of

89Zr-DFO-Pertuzumab.

Theranostics. 2020, 10 (4), 1746-1757.
2.1. Introduction
In recent years, 89Zr-labeled antibodies have emerged as promising agents for the positron
emission tomography (PET) imaging of cancer.1 Indeed, 89Zr is nearly ideally suited for
immunoPET because its physical half-life (t1/2 = 3.3 days) aligns perfectly with the biological halflife of full-length antibodies.2-4 Recently, two radioimmunoconjugates targeting different epitopes
of human epidermal growth factor receptor-2 (HER2) ―

89Zr-DFO-trastuzumab

and

89Zr-DFO-

pertuzumab ― have shown significant clinical potential in patients with HER2-positive breast
cancer.5, 6 Yet despite the promise of 89Zr-labeled antibodies, the current synthetic methodologies
used to create them are suboptimal at best. The majority of radioimmunoconjugates are produced
via random conjugation methods in which bifunctional chelators ― in the case of

89Zr,

desferrioxamine (DFO) ― are attached to the lysines of the antibody.7 Yet because antibodies have
several lysines distributed throughout their structure, this approach produces poorly defined and
heterogeneous immunoconjugates that can suffer from suboptimal immunoreactivity.
A variety of different site-specific bioconjugation methods have been developed to
circumvent these problems, including strategies based on thiol-reactive probes, peptide tags, and
non-canonical amino acids.7-9 The benefits of site-specific bioconjugation are clear. To wit,
irrespective of the modification method, site-specifically modified immunoconjugates have been
shown to be more homogeneous, better-defined, more reproducibly synthesized, and more effective
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in vivo than their randomly modified cousins.7, 10-14 Moreover, several reports have shown that
site-specifically modified radioimmunoconjugates in particular exhibit improved in vivo behavior
compared to randomly labeled analogues.15-19
Over the last half-decade, our laboratory and others have worked to develop
chemoenzymatic approaches to site-specific bioconjugation capable of selectively appending
cargoes — including fluorophores, chelators, and toxins — to the heavy chain glycans on the CH2
domain of an antibody’s Fc region.10, 14, 15, 20-23 These biantennary sugar chains are particularly
attractive sites for modification as they offer a pair of biochemically unique handles for
manipulation and lie far from the antigen-binding domains of the immunoglobulin. Our strategy
approach is predicated on three steps. First, one of two enzymes is used to truncate the glycans:
either -galactosidase (Gal, which removes the outermost monosaccharide) or endoglycosidase
(EndoS, which hydrolyzes the chitobiose core of the glycans, leaving only the innermost residue).
Second, a mutant, promiscuous galactosyltransferase [GalT-(Y289L)] is used to install azidemodified galactose residues (GalNAz) into the sugar chains. And finally, dibenzocyclooctynebearing cargoes are appended to the azide-bearing sugars via the strain-promoted azide-alkyne click
(SPAAC) reaction. We have demonstrated that this strategy produces well-defined, more
homogeneous immunoconjugates with excellent in vivo behavior using several model systems and
a range of different payloads, and we are currently bringing this technology to the clinic. 8, 15, 20
In the work at hand, we set out to explore the influence of site-specific bioconjugation on
the in vivo performance of radioimmunoconjugates. This investigation is fueled in large part by
recent results from our laboratory that suggest that the truncation of the heavy chain glycans of
radioimmunoconjugates can reduce their retention in healthy non-target organs and boost their
accretion in tumor tissue.24,

25

We hypothesize that the root of this phenomenon lies in the

conformational change that occurs upon the deglycosylation of the immunoglobulin. This change
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attenuates the binding of the immunoconjugate to FcRI, an Fc receptor that is expressed on the
surface of monocytes, macrophages, and tissue-resident macrophages in the liver.26,
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It is

important to note that we have focused on FcRI in this investigation because it is the only member
of the FcR family that is able to bind monomeric IgGs; the others ⎯ FcRII and FcRIII ⎯ prefer
to bind to immune-complexes.28 Due to its clinical relevance, we selected pertuzumab — a
monoclonal antibody that targets the HER2 antigen over-expressed in 20-30% of breast cancers —
for this proof-of-concept study.29,
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In fact, the first-in-human clinical trial of

89 Zr-DFO-

pertuzumab in patients with HER2-positive breast cancer was conducted in 2017.5 Here, we
synthesized three desferrioxamine-labeled pertuzumab immunoconjugates: one using traditional,
random bioconjugation methods (DFO-nsspertuzumab) and two using our chemoenzymatic
protocol (DFO-sspertuzumab-EndoS and DFO-sspertuzumab-Gal). Subsequently, we structurally
characterized the trio of constructs, interrogated their ability to bind recombinant HER2 as well as
human and mouse FcRI, explored their in vitro behavior with HER2-positive BT474 human breast
cancer cells, and evaluated their in vivo performance in two different mouse models of HER2expressing human breast cancer, including one using humanized NSG (huNSG) mice. Taken
together, the data clearly illustrate that site-specific bioconjugation not only produces more
homogeneous and well-defined radioimmunoconjugates than traditional methods but may also
improve their in vivo performance in certain mouse models and — potentially — patient
populations. While our laboratory and others have indeed previously noted the improved in vivo
performance of radioimmunoconjugates that have been modified on the heavy chain glycans, this
investigation represents the first exploration of why this may be the case.15, 16, 20
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2.2. Experimental Section
2.2.1. Reagents and General Procedures
All chemicals, unless otherwise noted, were acquired from Sigma-Aldrich or Fisher
Scientific and used as received without further purification. All water used was ultra-pure (>18.2
MΩcm-1), and dimethylsulfoxide was of molecular biology grade (>99.9%). DFO-nsspertuzumab,
DFO-sspertuzumab-βGal, and DFO-sspertuzumab-EndoS were prepared according to published
protocols and characterized via SDS-PAGE, MALDI-ToF mass spectrometry, and ELISA
according to previously reported methods.15, 20 [89Zr]Zr(oxalate) was produced and purified via the
89Y(p,n)89Zr

reaction at Memorial Sloan Kettering Cancer Center as previously described. Activity

measurements were made using a CRC-15R Dose Calibrator (Capintec, Inc.), and experimental
samples were counted on an Automatic Wizard2 γ–counter (PerkinElmer, Inc.). The radiolabeling
of the pertuzumab immunoconjugates with [89Zr]Zr4+ was performed according to published
procedures and monitored using silica-impregnated instant thin-layer chromatography (iTLC)
paper (Pall Corp.) on an AR-2000 radio-TLC plate reader (Bioscan, Inc.). Mice were implanted
with HER2-positive BT474 human breast cancer xenografts as previously reported, and PET
imaging and acute biodistribution experiments were performed according to published protocols
approved by the Institutional Animal Care and Use Committees of Hunter College, Weill Cornell
Medical College, and Memorial Sloan Kettering Cancer Center.15, 20
2.2.2. SDS-PAGE Analysis
The purified constructs ⎯ pertuzumab, DFO-nsspertuzumab, DFO-sspertuzumab-βGal, and
DFO-sspertuzumab-EndoS ⎯ were characterized via sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE). Briefly, 2 μg antibody (0.85 μL of a 5.89 mg/mL stock) were
combined with 31.65 μL H2O, 5 μL 500 mM dithiothreitol (NuPAGE® 10X Sample Reducing
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Agent, Life Technologies), and 12.5 μL 4X electrophoresis buffer (NuPAGE® LDS Sample
Buffer, Thermo Fisher, Eugene, OR). This mixture was then denatured by heating to 95°C for 10
min using a heat block. Subsequently, 20 μL of each sample was then loaded alongside an
appropriate molecular weight marker (Mark12TM stained standard, Life Technologies) onto a 1
mm, 10 well 4-12% Bis-Tris protein gel (Life Technologies) and run for ~4 h at 10 V/cm in MOPS
buffer. The completed gel was washed 3 times with H2O, stained using SimplyBlueTM SafeStain
(Life Technologies) for 1 h, and destained overnight in H 2O. The gel was then analyzed using an
Odyssey Infrared Gel Scanner (Li-Cor Biosciences, Lincoln, NE).
2.2.3. Size Exclusion Chromatography
Size exclusion chromatography was performed on a Shimadzu UFLC HPLC system. 100
µg (0.67 nmol) of each construct was run on an SEC column (SuperdexTM 200 Increase 10/300 GL,
GE Healthcare) in phosphate buffered saline for 40 min (flow rate: 0.75 mL/min) and the
absorbance was measured at 280 nm.
2.2.4. Flow Cytometry
Flow cytometry experiments were performed with HER2-positive BT474 cells. Native
pertuzumab and the immunoconjugates were incubated at 6 μg/mL in suspension with 10 6
cells/mL for 30 min on ice. Cells were washed by pelleting and resuspension and then incubated
with a goat anti-human IgG-AlexaFluor568 secondary antibody (Thermo Fisher Scientific) at 4
μg/mL. Subsequently, the cells were again washed by pelleting and resuspension three times and
then analyzed on a BD LSR II (BD Biosciences, San Jose, CA). Binding data was collected in
triplicate, averaged, and plotted.
2.2.5. FcRI Binding ELISA
Recombinant human Fc gamma RI/CD64, CF (R&D Systems # 1257-FC-050) was diluted to
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10 μg/mL in sterile PBS and 100 μL/well was coated overnight at 4°C onto an ELISA plate (Nunc
MaxiSorp® flat-bottom 96 well plate, Fisher Scientific). After a brief blocking period (40 min with
PBS containing 10% FCS), the immunoconjugates were diluted in a blocking buffer (0.5 or 50
μg/mL) and 100 μL/well were applied for 2 h at room temperature. As not to disrupt the Fc-FcγRI
interactions, the bound immunoconjugates were detected using 1: 5000 HRP-labeled anti human
IgG (JacksonImmunoResearch Laboratories, West Grove, PA). After a final wash step, TMB
substrate was used to develop the bound HRP secondary antibody, and the color reaction was
stopped with 2N H2SO4. Optical Densities at 450 nm were determined using a SpectraMax i3 plate
reader (Molecular Devices, San Jose, CA). Binding data was collected in triplicate, averaged, and
plotted.
2.2.6. Surface Plasmon Resonance
Binding affinities (KD) and kinetic constants (ka and kd) for pertuzumab as well as the three
DFO-modified immunoconjugates – DFO-nsspertuzumab, DFO-sspertuzumab-Gal and DFOsspertuzumab-EndoS

— were determined via surface plasmon resonance (SPR) on a Biacore T200

instrument (GE Healthcare).
First, in order to characterize the impact of bioconjugation on the immunoreactivity of
pertuzumab for its cognate antigen, SPR experiments (n = 3 per construct) with HER2 were
performed. To this end, pertuzumab or its DFO-modified immunoconjugates were captured as the
ligand on a Protein A sensor chip (29-1275-56, GE Healthcare) by diluting the IgG to a
concentration of 1 μg/mL in HBS-EP+ buffer (BR100188, GE Healthcare) and injecting it over a
Series S protein A sensor chip for 30 seconds at a flow rate of 5 μL/min. Next, purified recombinant
human HER2 protein (HE2-H822R Acro Biosystems) was used as the analyte and flowed over the
functionalized sensor chip. The binding kinetics were evaluated over a range of HER2
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concentrations in HBS-EP+ buffer (25 nM, 12.5 nM, 6.25 nM, 3.13 nM, 1.56 nM, 0.78 nM, 0.39
nM and 0.195 nM), with each concentration injected for 5 minutes at a flow rate of 5 µL/min to
facilitate binding with the immunoconjugate captured on the sensor chip. The dissociation phase
was evaluated by allowing the binding buffer (HBS-EP+) to flow (5 µL/min) over the sensor chip
for 900 s for the highest analyte concentration (25 nM) and 300 s for all other concentrations. The
regeneration buffer (10 mM Glycine-HCl pH 1.5) was then passed over the chip surface for 1 min
at a flow rate of 5 µL/min to achieve complete dissociation of the captured antibody and any
remaining immunocomplexes. And finally, HBS-EP+ buffer was flowed over the chip for 2 min at
5 µL/min to stabilize the protein A chip surface prior to the injection of the next sample.
Next, to investigate the impact of bioconjugation and deglycosylation on the interaction
between the immunoconjugates and Fc receptors, we turned to SPR experiments with the human
and murine variants of the high affinity Fc-receptor: FcRI. With respect to the former, a histidinetagged variant of recombinant human FcRI (500238; NovoPro Labs) was used as the ligand. A
Series S sensor chip CM5 (29401988; GE Healthcare) was functionalized with an anti-histidine
antibody using components from the His-capture kit (28995056; GE Healthcare) and the amine
coupling kit (BR-1000-50; GE Healthcare) following the standard procedure prescribed by the
application wizard on the Biacore T200. After the chip was functionalized, a 0.8 nM solution of
huFcR1 in running buffer (HBS-P+ buffer containing 50 M EDTA) was injected over flow cell 2
for 60 s at a flow rate of 10 L/min. Subsequently, high performance injections of various
concentrations of pertuzumab or its DFO-modified conjugates (100 nM, 50 nM, 25 nM, 12.5 nM,
6.25 nM, 3.13 nM, 1.56 nM, and 0.78 nM) were performed over flow cells 1 and 2 for 5 min at a
flow-rate of 30 L/min. The dissociation of the analyte was evaluated by allowing the running
buffer to flow over the chip surface for 5 min. Finally, the chip surface was regenerated using a 60
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s injection of 10 mM Glycine-HCl (His-capture kit) at a flow-rate of 30 L/min, followed by an
extra wash with the running buffer. A similar — though slightly modified — experimental set up
was used to evaluate the interaction between the immunoconjugates and murine FcRI (muFcR1).
Here, a 2.4 nM solution of histidine-tagged mouse FcRI (2074-FC; R&D Systems) was captured
on the same series S CM5 sensor chip as used above. Based on preliminary indications suggesting
rapid on- and off-rates, the association and dissociation phases for all of the pertuzumab-muFcRI
interactions were evaluated over a shorter time window: 120 s. The BIAcore T200 evaluation
software was used to analyze the kinetic data. A 1:1 fit (RI set to 0) was used to derive kinetic
constants for the interactions between the immunoconjugates and both HER2 and huFcRI. In
contrast, the rapid on- and off-rates observed in case of muFcRI warranted analysis using steadystate kinetics.
2.2.7. Radiolabeling with 89Zr
For each antibody construct, 400 µg (2.67 nmol) of immunoconjugate solution was diluted in
400 µL PBS, pH 7.4. [89Zr]Zr-oxalate (1300 µCi, 48.1 MBq) in 100 µL of 1.0 M oxalic acid was
adjusted to pH 7.0-7.5 with 1.0 M Na2CO3. After the bubbling of CO2 stopped, the 89Zr solution
was added to the antibody solution, and the resulting mixture was incubated at room temperature
for 1 h. The reaction progress was then assayed using iTLC using an eluent of 50 mM EDTA (pH
5). Subsequently, the reaction was quenched with 10 µL of 50mM of EDTA (pH = 5), and the
antibody construct was purified using size exclusion chromatography (Sephadex G-25 M, PD-10
column, GE Healthcare; dead volume = 2.5 mL, eluted with 500 µL fractions of PBS, pH 7.4). If
necessary, the antibody was concentrated via centrifugal filtration units with a 50,000 Da molecular
weight cut off (AmiconTM Ultra 4 Centrifugal Filtration Units, Millipore Corp. Billerica, MA). The
radiochemical purity of the final radiolabeled bioconjugate was assayed by iTLC using 50 mM
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EDTA (pH 5) as an eluent. In the iTLC experiments, free [89Zr]Zr4+ cations and [89Zr]-EDTA elute
with the solvent front, while the radioimmunoconjugate remains at the baseline.
2.2.8. Bead-based Immunoreactivity Assay
A bead-based assay was used to determine the immunoreactive fraction of each of the
immunoconjugates. To this end, 20 µL of Ni-NTA beads (Thermo Fisher Scientific # 88831) were
transferred to EppendorfTM LoBind microcentrifuge tubes, and 380 µL of PBS-T (PBS with 0.05%
Tween-20) was added. The tubes were vortexed for 5 sec, spun down, and placed on a DynaMag2 magnetic rack (Invitrogen) for 30-45 sec. Once the beads settled, the supernatant was aspirated
and discarded. The tubes were then placed on the magnetic rack, and 400 µL of PBS-T was added.
3 of the tubes were capped, labeled C1-C3, and set aside as controls.
Next, to prepare the antigen-coupled Ni-NTA beads, 1 µg (10 µL of 0.1 mg/mL dilution) of the
His-tagged HER2 antigen (Acro Biosystems, Newark, DE) was added to the rest of the tubes
(labeled T1-T3), and the tubes were placed on a rotating platform for 15 min. The tubes were then
spun down and placed onto the magnetic rack, and the supernatant was aspirated. The same
sequence of steps was repeated to wash the beads with 400 µL of PBS-T. Prior to addition of the
radioimmunoconjugate in the next step, the beads were resuspended in 399 µL of 1% BSA-PBS.
Subsequently, each radioimmunoconjugates was diluted to 1 ng/µL with PBS, and 1 ng of the
diluted radioimmunoconjugate was added to all the tubes. The tubes were vortexed for 5 seconds
and placed on the rotating platform for 30 min. The tubes were once again spun down and placed
on the magnetic. The supernatant and two washes (400 µL each) were collected. Finally, the beads,
supernatant, and washes were measured for radioactivity on a gamma counter (Automatic Wizard 2
ɣ-counter, Perkin Elmer, Inc., Waltham, MA). The immunoreactive fraction was then calculated as
the fraction of activity associated with the beads corrected for the fraction of non-specific binding
observed in the control samples.
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2.2.9. Radioimmunoconjugate Stability Assays
The stability of the radioimmunoconjugates with respect to radiochemical purity and loss of
radioactivity from the antibody was investigated via incubation of the antibodies in human serum
for 7 days at 37°C (n = 3). At predetermined time intervals, the radiochemical purity of the
radioimmunoconjugates was determined via iTLC with an eluent of 50 mM EDTA pH 5.0.
2.2.10. PET Imaging
PET imaging experiments were conducted on a microPET Focus rodent scanner (Concorde
Microsystems). Mice (athymic nude, NSG, or humanized NSG mice) bearing subcutaneous BT474
xenografts (left shoulder, 60-120 mm3, 25-30 days after inoculation) were administered the
radioimmunoconjugates [175-210 μCi, 6.5-7.8 MBq (40-80 μg) in 200 μL of saline] via tail vein
injection. Approximately 5 min before PET imaging, the mice were anesthetized by inhalation of
a 2% isoflurane (Baxter Healthcare):oxygen gas mixture and placed on the scanner bed. Anesthesia
was maintained using a 1% isoflurane mixture. PET data for each mouse were recorded via static
scans at 24, 48, 96 and 144 h post-injection (n = 4-5 per group).
2.2.11. Acute Biodistribution Experiments
Mice (athymic nude or humanized NSG mice) bearing subcutaneous BT474 xenografts (left
shoulder; 60-120 mm3) were randomized before the study and were administered the
radioimmunoconjugates [20 µCi, 0.74 MBq (10 µg) in 200 µL of saline] via tail vein injection.
Subsequently, the animals (n = 5 per group) were euthanized by CO 2(g) asphyxiation at 24, 48, and
120 h p.i., and 13 tissues (including the tumor) were removed, washed, dried, weighed, and counted
in a gamma counter (PerkinElmer, Inc.). The number of counts in each tissue were background and
decay corrected to the time of injection and converted to activity units (µCi) using a calibration
curve generated from known standards. The %ID/g for each tissue sample was then calculated by

32

normalization to the total activity injected and the mass of each tissue.
2.2.12. Statistical Analysis
Data were analyzed by the unpaired, two-tailed Student’s t test. Differences at the 95%
confidence level (p < 0.05) were considered to be statistically significant.
2.3. Results
2.3.1. Model System, Synthesis, and Characterization
Assembling the three components of the model system for this proof-of-concept study was
fairly straightforward. Zirconium-89 (t1/2 ~ 3.3 d) is the radionuclidic gold standard for
immunoPET, and desferrioxamine (DFO) remains the only clinically-employed chelator for the
radiometal (though several other options are on the cusp of being tested in the clinic).1 The identity
of the antibody presented a wider array of options, but the HER2-targeting pertuzumab emerged as
the ideal candidate. Indeed, the recent clinical translation of

89Zr-DFO-pertuzumab

at Memorial

Sloan Kettering Cancer Center not only illustrated the clinical promise of the radiotracer but also
⎯ and just as importantly ⎯ paved the way for future clinical comparisons with a site-specifically
labeled variant of the radioimmunoconjugate.
The non-site-specifically modified immunoconjugate ⎯ DFO-nsspertuzumab ⎯ was
prepared according to published procedures via the random conjugation of an isothiocyanatebearing variant of DFO (p-SCN-Bn-DFO) to the lysines of the antibody (Figure 2.1A).31
MALDI-ToF analysis of the resulting immunoconjugate – DFO-nsspertuzumab – revealed
an average of 1.4 ± 0.4 DFO attached per antibody (Figures A.2.1-2.6 and Table A.2.1). The sitespecifically modified immunoconjugates were synthesized using a chemoenzymatic method
developed in our laboratory.15, 20 Briefly, pertuzumab was first treated with one of two enzymes in
order to expose terminal N-acetylglucosamine residues: β-1,4-galactosidase, which removes the
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terminal galactose residues of the glycans, or EndoS, which hydrolyzes the chitobiose core of the
asparagine-linked glycans (Figure 2.1B-C). The resulting constructs were then incubated with the
promiscuous galactosyltransferase Gal-T1(Y289L) and the monosaccharide UDP-GalNaz to
incorporate azides into the remaining glycans. Finally, the chelator desferrioxamine (DFO) was
introduced via the strain promoted alkyne-azide cycloaddition between dibenzocyclooctyne
(DBCO)-DFO and the azide-bearing glycans, ultimately providing DFO-sspertuzumab-βGal or
DFO-sspertuzumab-EndoS. Sodium dodecyl sulfate-polyacrylamine gel electrophoresis (SDSPAGE) confirmed the site-specificity of the modification (Figure A.2.7), size exclusion
chromatography illustrated that none of the immunoconjugates formed aggregates (Figures A.2.82.11), and MALDI-ToF mass spectrometry revealed degrees of labeling of 2.6 ± 0.1 DFO/mAb for
DFO-sspertuzumab-βGal and 1.3 ± 0.2 DFO/mAb for DFO-sspertuzumab-EndoS (Table A.2.1).
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Figure 2.1. The construction of the pertuzumab immunoconjugates: DFO-nsspertuzumab (top),
DFO-sspertuzumab-βGal (middle), and DFO-sspertuzumab-EndoS (bottom).
2.3.2. In Vitro Characterization
The ability of the immunoconjugates to bind HER2 was first interrogated via SPR assays.
These experiments revealed that native pertuzumab, DFO-nsspertuzumab, DFO-sspertuzumab-βGal,
and DFO-sspertuzumab-EndoS all exhibit nearly identical values for KD (~0.14-0.16 nM), ka (1.92.1  105 M-1s-1), and kd (2.7-3.1  10-5 M-1) (Table 2.1 and Figure A.2.12). These results were
confirmed with flow cytometry experiments using HER2-expressing BT474 human breast cancer
cells (Figure A.2.13). Taken together, these data suggest that the switch to site-specific
bioconjugation does not perturb the ability of the immunoconjugates to bind their target antigen.

Dissociation constant (KD)
On-rate (ka)
Off-rate (kd)

pertuzumab

DFO-nsspertuzumab

DFO-sspertuzumab-βGal

DFO-sspertuzumab-EndoS

0.16  0.01 nM
2.02  105 M-1s-1
3.14 x 10-5 s-1

0.15  0.01 nM
1.97  105 M-1s-1
3.01  10-5 s-1

0.14  0.01 nM
2.09  105 M-1s-1
2.90  10-5 s-1

0.14  0.04 nM
1.92  105 M-1s-1
2.72  10-5 s-1

Table 2.1. SPR-derived binding parameters for the various pertuzumab immunoconjugate and
HER2.
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In light of our recent work on the interplay between the glycosylation, Fc receptor binding,
and in vivo performance of radioimmunoconjugates (see Discussion), we also probed the binding
of the three immunoconjugates to murine and human FcRI via ELISA and SPR. The ELISA data
illustrate that DFO-sspertuzumab-EndoS exhibits attenuated binding to huFcRI compared to DFOnsspertuzumab

(Figure 2.2A). Somewhat surprisingly, DFO-sspertuzumab-βGal also exhibits

decreased binding to huFcRI, though not to the same degree as its more truncated counterpart.
These data are generally reinforced by the ELISA experiments with muFcRI, though a higher
concentration of immunoconjugate was needed to generate meaningful data due to the lower
affinity of the murine receptor for the human IgGs. Here, DFO-sspertuzumab-EndoS again displays
reduced binding to muFcRI compared to DFO-nsspertuzumab, while DFO-sspertuzumab-βGal
occupies a middle ground.
Broadly speaking, the SPR data confirm the ELISA findings (Figure 2.2B-D and Table
2.2)

and

are

in

strong

agreement

with

our

recent

findings

on

deglycosylated

radioimmunoconjugates.24 With respect to huFcRI, it is clear that the truncation of the heavy
glycans exerts a strong influence on binding. More specifically, native pertuzumab (4.7  0.2  109

M), DFO-nsspertuzumab (4.1  0.1  10-9 M), and DFO-sspertuzumab-βGal (4.7  0.2  10-9 M)

exhibit similar binding affinities for the receptor, while that of DFO-sspertuzumab-EndoS is
weaker: 17.4  0.3  10-9 M (Table 2.2). A similar trend is seen in the kinetic parameters. Here,
the EndoS-modified immunoconjugate has a slower on-rate and an accelerated off-rate than the
other immunoconjugates. These differences translate to a shorter interaction half-time for DFOsspertuzumab-EndoS
nsspertuzumab

(3.0  0.1 min) compared to native pertuzumab (7.3  0.1 min), DFO-

(7.4  0.4 min), and DFO-sspertuzumab-βGal (8.0  0.3 min).

The parallel examination of the interactions between the pertuzumab immunoconjugates
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and murine FcRI revealed a similar overall trend but also a few key differences. While all four
immunoconjugates displayed 50-fold lower binding constants for muFcRI compared to huFcRI,
unmodified pertuzumab (2.5  0.1  10-7 M), DFO-nsspertuzumab (2.5  0.2  10-7 M), and DFOsspertuzumab-βGal

(2.1  0.1  10-7 M) still retained higher affinities than DFO-sspertuzumab-

EndoS (1.1  0.1  10-6 M). Furthermore, the quartet of immunoconjugates displayed rapid on- and
off-rates for binding to muFcRI, thereby necessitating the analysis of the interaction using steadystate kinetics and thus abrogating the determination of kinetic parameters.
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Figure 2.2. Comparative SPR and ELISA analysis of the interaction between pertuzumab
immunoconjugates and recombinant human versus mouse FcRI. (A) ELISA data demonstrating
the binding of the immunoconjugates to huFcγRI (10 μg/mL; left) and muFcγRI (10 μg/mL; right);
(B) Sensorgrams showing robust dose-response curves and kinetic profiles for the binding of
various concentrations of native pertuzumab and the DFO-bearing immunoconjugates to huFcγRI;
(C) Bar graphs demonstrating the correlation between deglycosylation and binding affinity (K D),
on-rate (ka), off-rate (kd) and half-life (t1/2). The binding affinity, kinetic constants and half-lives
for each of the DFO-conjugates were compared with those obtained for unmodified pertuzumab;
(D) Sensorgrams showing robust dose-response curves and kinetic profiles for the binding of
various concentrations of native pertuzumab and the DFO-bearing immunoconjugates to muFcγRI.
Statistically significant relationships are indicated with asterisks. * = p < 0.05, ** = p < 0.005, ***
= p < 0.0005, **** = p < 0.00001.
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pertuzumab

DFO-nsspertuzumab

DFO-sspertuzumabβGal

DFO-sspertuzumabEndoS

huFcRI
Dissociation
constant (KD), nM
On-rate (ka), M-1s-1
Off-rate (kd), s-1
Half-time (t1/2), min

4.70  0.18

4.08  0.09

4.68  0.18

17.43  0.25

3.36  0.08  105
1.58  0.03  10-3

3.83  0.22  105
1.56  0.08  10-3

3.08  0.21  105
1.44  0.05  10-3

2.22  0.09  105
3.87  0.19  10-3

8.0  0.3

3.0  0.1

Dissociation
constant (KD), M

0.25  0.01

0.21  0.02

1.08  0.11

7.3  0.1

7.4  0.4
muFcRI
0.25  0.02

Table 2.2. SPR-derived binding parameters for the various pertuzumab immunoconjugate and
human and murine FcRI
2.3.3. Radiolabeling
The immunoconjugates were subsequently radiolabeled with 89Zr using standard protocols,
producing a trio of radioimmunoconjugates in >95% radiochemical yield and >99% radiochemical
purity with similar specific activities of 96.2 ± 1.1 MBq/mg (14.4 ± 0.2 GBq/μmol) for 89Zr-DFOnsspertuzumab,

96.2 ± 1.5 MBq/mg (14.4 ± 0.2 GBq/μmol) for 89Zr-DFO-sspertuzumab-βGal, and

97.7 ± 0.7 MBq/mg (14.7 ± 0.1 GBq/μmol) for

89Zr-DFO-sspertuzumab-EndoS.

A subsequent

stability study in human serum at 37 °C revealed that over the course of a week, the three
radioimmunoconjugates demonstrated >85% stability (Figure A.2.14). Similarly, a bead-based
HER2

binding

assay

yielded

nearly

identical

immunoreactive

radioimmunoconjugates: 79 ± 4, 92 ± 2, 88 ± 3 for
sspertuzumab-βGal,

fractions

for

the

89 Zr-DFO-nsspertuzumab, 89Zr-DFO-

and 89Zr-DFO-sspertuzumab-EndoS, respectively.

2.3.4. In Vivo Behavior
In order to compare the in vivo performance of the radioimmunoconjugates, PET imaging
and biodistributions experiments were first conducted in athymic nude mice bearing subcutaneous
HER2-expressing BT474 xenografts. PET images were collected at 24, 48, 96 and 144 h after the
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intravenous administration of each radioimmunoconjugate (200 μCi, 7.4 MBq, 70-80 μg). As early
as 24 h post injection (p.i.) the tumors could easily be delineated in the images acquired with all
three radioimmunoconjugates (Figure 2.3A). Over the course of 6 days, the activity concentrations
in the tumor increased dramatically, while the uptake in the blood decreased apace. The
biodistribution data confirm the observations made via PET: as the experiment progressed, activity
concentrations in the tumor increased, ultimately producing excellent tumor-to-healthy organ
activity concentration ratios (Figure 2.3B; Tables A.2.2 and A.2.3). Critically, very few
qualitative or quantitative differences were found between the images and uptake values obtained
with each of the radioimmunoconjugates.

40

Figure 2.3. (A) Planar (left) and maximum intensity projection (MIP, right) PET images of athymic
nude mice bearing subcutaneous BT474 xenografts injected with the three 89Zr-DFO-pertuzumab
radioimmunoconjugates (179 – 192 μCi, 6.6 – 7.1 MBq, 85 – 92 μg, in 200 μl 0.9% sterile saline).
(B) Biodistribution data for athymic nude mice bearing HER2-expressing BT474 xenografts
injected with 89Zr-DFO-nsspertuzumab, 89Zr-DFO-sspertuzumab-EndoS, or 89Zr-DFOsspertuzumab-Gal (lateral tail vein injection, 15 – 20 µCi, 0.56 – 0.74 MBq, 6 – 9 µg).
As we have noted, the initial in vivo experiments did not reveal any differences between the
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performance of the three radioimmunoconjugates. However, pertuzumab is a humanized antibody,
athymic nude mice express murine (rather than human) FcRI, and — as we have seen — the
affinity of the pertuzumab-based immunoconjugates for muFcRI is rather low. In order to
investigate this phenomenon in a more appropriate mouse model, we turned to humanized NOD
scid gamma (huNSG) mice. HuNSG mice are NSG mice that were sub-lethally irradiated 3 weeks
after birth and then reconstituted with human hematopoietic stem cells in order to facilitate the
expression of a functional human immune system, including human NK cells, dendritic cells, T
cells, B cells, and monocytes.32-35 PET imaging was performed using huNSG mice bearing
subcutaneous HER2-expressing BT474 xenografts (Figure 2.4A). The images reveal stark
differences between the randomly-labeled radioimmunconjugate and the two site-specifically
labeled variants. To wit, 89Zr-DFO-nsspertuzumab produces lower tumor uptake and higher activity
concentrations in healthy organs — specifically, the liver, spleen, and bones — than
sspertuzumab-EndoS

89Zr-DFO-

and 89Zr-DFO-nsspertuzumab-Gal. The biodistribution data at 120 h p.i. tell

a slightly more nuanced story (Figure 2.4B; Tables A2.4 and A2.5).

89Zr-DFO-sspertuzumab-

EndoS produces higher activity concentrations in the tumor compared to 89Zr-DFO-nsspertuzumab
(111.8 ± 39.9 %ID/g vs. 46.1 ± 16.5 %ID/g; p < 0.05) as well as lower uptake in the liver (4.7 ±
0.8 %ID/g vs 10.3 ± 2.7 %ID/g; p < 0.05) and spleen (13.1 ± 4.0 %ID/g vs 44.8 ± 7.9 %ID/g; p <
0.05). Interestingly, the biodistribution of 89Zr-DFO-nsspertuzumab-Gal presents an intermediate
case. Its activity concentration in the tumor (77.5 ± 12.6 %ID/g) is greater than that of 89Zr-DFOnsspertuzumab,

though statistically significant differences in the uptake of the two

radioimmunoconjugates in the liver and spleen were not observed.
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Figure 2.4. (A) Planar (left) and maximum intensity projection (MIP, right) PET images of huNSG
mice bearing subcutaneous BT474 xenografts collected between 24 and 144 h after the
administration of the three radioimmunoconjugates (209 – 218 μCi, 7.7 – 8.1 Mbq, 80 – 83 μg, in
200 μl 0.9% sterile saline); (B) Biodistribution data for 89Zr-DFO-nsspertuzumab, 89Zr-DFOsspertuzumab-βGal, and 89 Zr-DFO-sspertuzumab-EndoS 144 hours following administration in
huNSG mice bearing subcutaneous HER2-expressing BT474 xenografts. T = tumor; L = liver; S =
spleen; B = bone. * = p < 0.05.
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2.4. Discussion
While the advent of radioimmunoconjugates for nuclear imaging and therapy has coincided
with the rise of ‘precision medicine’, the strategies used to create these tools have long remained
surprisingly imprecise. The random conjugation of bifunctional chelators to the lysine residues of
immunoglobulins is an undeniably simple approach that nonetheless produces poorly defined and
heterogeneous immunoconjugates and risks compromising their bioactivity. The chemoenzymatic
bioconjugation methodology that we have developed over the last five years offers a facile —
though admittedly slightly more complex — route to better defined, more homogeneous, and highly
immunoreactive agents. The key, of course, lies in leveraging the heavy chain glycans, as these
biantennary sugar chains provide a handle for selective manipulation, a limited number (i.e. 2 or 4)
of conjugation sites, and distance from the immunoglobulin’s antigen-binding domains.
In the case at hand, the very nature of the modification strategy dictates that both DFOsspertuzumab-EndoS

and DFO-nsspertuzumab-Gal are better defined and more homogeneous than

DFO-nsspertuzumab. Yet beyond this fundamental — and important — difference, the three
immunoconjugates proved very similar according to the metrics upon which immunoconjugates
are traditionally evaluated. SPR assays revealed that each boasts sub-nanomolar KD values for
HER2 (0.14 nM – 0.16 nM) that are essentially identical to that of the parent antibody, findings
that were reinforced by FACS with HER2-expressing BT474 cells. The similarities continued upon
radiolabeling:

89Zr-DFO-nsspertuzumab 89Zr-DFO-sspertuzumb-EndoS,

and DFO-nsspertuzumab-

Gal were produced in similar radiochemical yields and radiochemical purities and exhibited
nearly identical specific activities, stabilities, and immunoreactivities. Clearly, this approach to
bioconjugation provides structural benefits without any attendant costs when it comes to antigen
binding or radiosynthesis.
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Things become more interesting — and more complicated — when we consider that the
manipulation of the heavy chain glycans is not necessarily benign. As we have noted, the heavy
chain glycans play an important role in the structure of immunoglobulins and, as a result, their
ability to bind Fc receptors, most notably FcRI. We recently explored the interplay between the
truncation of the heavy chain glycans, FcRI binding, and the in vivo behavior of randomlymodified radioimmunoconjugates using a series of 89Zr-labeled variants of the HER2-targeting
antibody trastuzumab.24 More specifically, we observed that the truncation (via EndoS) or removal
(via PNGaseF) of the heavy chain glycans of 89Zr-DFO-trastuzumab attenuated the binding of the
radioimmunoconjugates to FcRI and improved in vivo performance in tumor-bearing NSG and
huNSG mice. Critically, our results are corroborated by the work of others on antibody-drug
conjugates and fluorophore-modified antibodies.36, 37
This investigation extends our previous work to include a systematic evaluation of
immunoconjugates created using both chemoenzymatic methods of bioconjugation. Both of the
site-specifically modified immunoconjugates in this study have altered glycans: those of DFOsspertuzumab-Gal

have simply been modified by the addition (via SPAAC) of DFO, while those

of DFO-sspertuzumab-EndoS have been truncated and modified with the chelator. These two
bioconjugation pathways had little influence on the ability of the immunoconjugates to bind HER2
(vide supra), but they did impact their ability to bind human and murine FcγRI. Both the ELISA
and SPR data illustrate that DFO-sspertuzumab-EndoS exhibits attenuated binding to huFcγRI
compared to native pertuzumab and DFO-nsspertuzumab, with the SPR data revealing both
thermodynamic and kinetic effects. While the immunoconjugates displayed lower binding
affinities for muFcγRI across the board, DFO-sspertuzumab-EndoS again exhibited attenuated
binding compared to the trio of fully glycosylated analogues according to both SPR and ELISA.
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Things become more complicated with DFO-sspertuzumab-Gal. In this case, both the ELISA and
the SPR data agree that the immunoconjugate exhibits similar affinity to native pertuzumab and
DFO-nsspertuzumab for muFcγRI. In the case of huFcγRI, however, the ELISA and SPR data
diverge slightly. The ELISA data shows that DFO-sspertuzumab-Gal displays a decreased affinity
for huFcγRI compared to DFO-nsspertuzumab and DFO-sspertuzumab-EndoS, while the SPR data
suggest that its binding to huFcγRI is nearly identical to that of the two fully glycosylated
analogues. These slight deviations may simply be the result of inherent differences between the
assays, especially since some small differences in the kinetic parameters of the binding of DFOsspertuzumab-Gal

to huFcγRI can be seen in the SPR data.

With the relationship between glycans-specific bioconjugation and FcγRI binding largely
established, the next step was to investigate whether these differences translate into changes in in
vivo performance. As we have discussed (see Results), the three radioimmunoconjugates ⎯ 89ZrDFO-nsspertuzumab,

89Zr-DFO-sspertuzumab-EndoS, 89Zr-DFO-sspertuzumab-Gal

⎯ exhibited

all but identical behavior in athymic nude mice, suggesting that neither the increased homogeneity
nor the attenuated FcγRI binding conferred by site-specific bioconjugation translates to significant
in vivo improvements in this particular mouse model. These results are similar to those observed
in our previous work and likely stem from the presence of endogeneous murine IgG, the model’s
expression of muFcγRI (rather than huFcγRI), and the immunoconjugates’ lower binding affinities
for muFcγRI compared to huFcγRI.24, 38, 39
The results in the huNSG mice ⎯ which, of course, express huFcγRI rather than muFcγRI
⎯ tell a more interesting story. In this model,

89Zr-DFO-sspertuzumab-EndoS

exhibited lower

activity concentrations in the liver and spleen and higher uptake in the tumor than

89Zr-DFO-

nsspertuzumab,

89Zr-DFO-

results consistent with reductions in the interaction between
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sspertuzumab-EndoS

and FcγRI receptors expressed by monocytes, macrophages, and tissue-

resident macrophages in the liver and spleen. The more subtle differences between the tumoral,
hepatic, and splenic activity concentrations of
nsspertuzumab

89Zr-DFO-sspertuzumab-Gal

and

89Zr-DFO-

suggest an intermediate case that may relate to the less pronounced differences

between the FcγRI binding of the two radioimmunoconjugates or to the increased homogeneity of
the former relative to the latter. In light of these data, however, it is important to reinforce that
huNSG mice are far from a flawless animal model. To wit, while they do express endogenous IgG
(202 ± 67 µg/mL), the lack of class switching from the isotype IgM to the isotype IgG results in
significantly lower titers than in immunocompetent strains and most human patients. This
phenomenon can most likely be linked to the lack of B-cell maturation in huNSG mice due to the
absence of follicular dendritic cells, germinal centers, and functional lymph nodes. 32, 33, 40 As a
result, huNSG mice may not provide the most accurate reflections of the behavior of these
‘immune-silent’ radioimmunoconjugates in immunocompetent patients. To remedy this limitation,
we are currently working with collaborators to build and utilize murine models of disease that offer
even more clinically relevant FcR expression profiles and recapitulations of the human immune
environment.
2.5. Conclusion
In the preceding pages, we have demonstrated that the site-specific bioconjugation of
antibodies via the manipulation of the heavy chain glycans not only facilitates the reproducible
synthesis of better-defined and more homogenous immunoconjugates but can also provide
radiotracers with improved in vivo performance. More specifically, compared to a traditional
approach to antibody modification, the site-specific bioconjugation of pertuzumab using EndoS
produces well-defined and highly immunoreactive immunoconjugates with attenuated binding to
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murine and human FcRI. This

approach

improves

in vivo

behavior in certain

immunocompromised mouse models (i.e. huNSG), a result that can have important implications
for preclinical research. In retrospect, the lack of any fundamental differences in the antigenbinding behavior of the radioimmunoconjugates upon site-specific bioconjugation was actually
advantageous, as it allowed us to parse between changes in biodistribution due to differences in
immunoreactivity and changes in biodistribution due to differences in FcRI binding (vide infra).
It remains unclear whether this phenomenon could prove beneficial in the context of clinical
immunoPET, though we hypothesize that it is most likely to improve imaging results in
immunosuppressed patients with low titers of endogeneous IgG. Moving forward, we plan to
interrogate the utility of this phenomenon in the context of radioimmunotherapeutics and antibodydrug conjugates. Furthermore ⎯ and undeniably more importantly ⎯ an upcoming clinical trial
comparing the in vivo performance of 89Zr-DFO-nsspertuzumab and 89Zr-DFO-sspertuzumab-EndoS
will certainly help resolve the question of the applicability of this work to human immunoPET.
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Chapter 3 : [89Zr]Zr-DFO-AR20.5: A MUC1-Targeting
ImmunoPET Probe
This chapter is an adaptation of unpublished work from Fung, K.; Vivier, D.; Sharma, S. K.;
Sarbisheh, E. K.; Keinänen, O.; Price, E. W.; Zeglis, B. M. [89Zr]Zr-DFO-AR20.5: A MUC1Targeting ImmunoPET Probe.
3.1. Introduction
Mucins are high molecular weight transmembrane glycoproteins that are expressed on the
surface of normal and malignant epithelial cells and play a diverse collection of roles, ranging from
the protection of the cell surface to the regulation of cellular adhesion. 1-3 MUC1 (also known as
CA15.3 or polymorphic epithelial mucin) is a tumor-associated mucin that is over-expressed in
most adenocarcinomas, including breast, pancreatic, and epithelial ovarian cancer. 4-9 The
overexpression and aberrant expression of MUC1 has been linked to tumor aggressiveness and
metastasis, poor response to therapy, and poor survival in several tumor types. 10 The role of MUC1
in ovarian cancer provides a representative case.11 To wit, MUC1 is highly expressed in both
primary epithelial ovarian cancer as well as the vast majority of cases of metastatic disease. 7, 10
Moreover, patients with metastatic, treatment-resistant ovarian cancer present elevated levels of
MUC1, with >90% producing antibodies against the antigen.10,

12, 13

Given its role in both

transformation and metastatic progression, MUC1 has remained an enticing therapeutic target for
almost three decades.10 A wide variety of MUC1-targeted therapies have been developed over the
years, including peptide-, protein-, and antibody-based vaccines, therapeutic antibodies, CAR-T
cells, and alpha and beta particle-emitting radioimmunoconjugates.3, 10, 14-23 Yet the field’s interest
in MUC1-targeted therapeutics has ebbed and flowed during this period, as preclinical successes
have proven difficult to recapitulate in the clinic. Recent years, however, have played witness to a
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reinvigoration of the area in response to the advent of checkpoint inhibitor therapy.24-26
The last ten years have played witness to a steady increase in the use of 89Zr-labeled antibodies as
PET imaging agents for the staging, treatment planning, and treatment monitoring of a range of
cancers.27-33 In light of this movement, the therapeutic interest in MUC1, and its role as a prognostic
biomarker, we set out to create an immunoPET probe that could be used for clinical diagnostic and
theranostic imaging of MUC1-expressing malignancies. The monoclonal antibody that forms the
foundation of our imaging agent is AR20.5, a murine IgG capable of binding MUC1 with high
affinity and specificity.9 While MUC1 is expressed by normal epithelial cells and cancer cells, the
protein is aberrantly underglycosylated in cancer cells.34 This difference in glycosylation state
between the epitopes of MUC1 expressed by healthy and malignant tissues has been exploited to
create several antibodies capable of specifically binding the tumor-associated antigen, including
AR20.5.9 To wit, AR20.5 binds in a glycosylation-dependent manner to tandem repeat peptide
sequence ⎯ i.e. DTRPAP ⎯ of MUC1, a site that is only accessible in tumor-associated epitopes
of the mucin.35 The therapeutic mechanism of AR20.5 is predicated on the antibody forming
immune complexes with circulating MUC1 or MUC1-expressing tumor cells and subsequently
inducing an immune response to the tumor itself.3 A Phase I clinical trial employing AR20.5 as a
monotherapy in 17 patients with MUC1-expressing cancers found that the antibody was generally
well tolerated and induced MUC1-specific immune responses but did not produce any anti-tumor
activity.3 More recently, a therapeutic regimen of AR20.5 in combination with anti-programmed
death-ligand (PD-L1) and polyinosinic-polycytidylic acid (PolyICLC) was explored in mouse
models of pancreatic cancer and found to produce MUC1-specific immune responses that suppress
tumor growth.36
In the manuscript at hand, we report the synthesis, characterization, and in vivo evaluation
of [89Zr]Zr-DFO-AR20.5 in two murine models of MUC1-expressing ovarian cancer. We have
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chosen ovarian cancer as the model system for this investigation because it is the fifth leading cause
of cancer deaths amongst women ⎯ with ~14,000 deaths in the United States alone in 2018 ⎯
and, as we have mentioned above, because the overexpression of MUC1 has been linked to
aggressiveness, invasiveness, metastatic potential, and resistance to therapy in the disease. 11, 13, 37
Ultimately, we envision deploying [89Zr]Zr-DFO-AR20.5 for the immunoPET of all MUC1expresing malignancies, both as a standalone diagnostic and prognostic tool and as a theranostic
imaging companion to AR20.5 itself and other MUC1-targeted therapeutics. Finally, it is important
to note that this investigation is admittedly not the first attempt to create a MUC1-targeted
radiopharmaceutical for nuclear imaging. Indeed, several reports of MUC1-targeted PET and
SPECT agents appear in the literature, including radioimmunoconjugates labeled with 111In, 99mTc,
and 64Cu, a pretargeted approach based on 68Ga, and ⎯ most recently ⎯ a 89Zr-labeled antibody.3843

Nonetheless, we believe that the limitations of these earlier imaging strategies, the recent

resurgence in MUC1-targeted therapeutics, and the therapeutic potential of AR20.5 combine to
form the basis of a strong rationale for the development of [89Zr]Zr-DFO-AR20.5.
3.2. Experimental
3.2.1. Materials and Methods
Unless otherwise noted, all chemicals were purchased from Sigma-Aldrich (St. Louis, MO)
or Fisher Scientific (Pittsburgh, PA) and were used without further purification. All water used was
ultrapure (>18.2 MΩcm-1 at 25 °C), and dimethylsulfoxide was of molecular biology grade
(>99.9%). p-SCN-Bn-DFO was purchased from Macrocyclics, Inc. (Plano, TX). MALDI-ToF
mass spectrometry was performed according to previously reported methods, and service was
provided by the Alberta Proteomics and Mass Spectrometry Facility (University of Alberta,
Alberta, Canada). 89Zr was produced and purified via the 89Y(p,n)89Zr reaction at Memorial Sloan
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Kettering Cancer Center as [89Zr]Zr-oxalate in 1.0 M oxalic acid. The AR20.5 antibody was
obtained from Oncoquest, Inc. (Edmonton, Alberta), and mouse immunoglobulin G (mIgG) was
purchased from Thermo Fisher Scientific (Waltham, MA). All in vivo experiments were performed
in accordance with published protocols approved by the Institutional Animal Care and Use
Committees of Hunter College, Weill Cornell Medical College, and Memorial Sloan Kettering
Cancer Center.
3.2.2. Instrumentation
All instruments were calibrated and maintained according to standard quality control
practices and procedures. UV-Vis measurements were taken on a Shimadzu BioSpec-nano Microvolume UV-Vis Spectrophotometer (Shimadzu Scientific Instruments, Kyoto, Japan). Activity was
measured using a CRC-15R Dose Calibrator (Capintec, Inc., Ramsey, NJ), and biodistribution
samples were counted on a calibrated Automatic Wizard2 ɣ-counter (PerkinElmer, Inc., Waltham,
MA). The radiolabeling of the immunoconjugate was monitored using glass-fiber, silicaimpregnated instant thin-layer chromatography (iTLC) paper (Pall Corp., East Hills, NY) and
analyzed on an AR-2000 radio-TLC plate reader using Winscan Radio-TLC software (Bioscan,
Inc., Washington, D.C.).
3.2.3. DFO modification of antibodies
AR20.5 (800 µg, 5.4 nmol) was dissolved in 500 µL of Chelex-treated (Chelex® 100 Resin,
Bio-Rad Laboratories, Inc.) phosphate-buffered saline (Chelex PBS, pH 7.4), and the pH of the
solution was adjusted to 8.8-9.0 with Na2CO3 (0.1 M). 5 equivalents of p-SCN-Bn-DFO (13.5 µL,
1.5 mg/mL in DMSO) was added to the solution in small aliquots. The resulting solution was
incubated at 37°C for 1 hour with shaking at 500 rpm. The DFO-modified antibody was then
purified using size exclusion chromatography (Sephadex G-25 M, PD-10 column, GE Healthcare;
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dead volume: 2.5 mL, eluted with 2 mL of Chelex PBS, pH 7.4) and concentrated using centrifugal
filtration units with a 50,000 Da molecular weight cut-off (AmiconTM Ultra 2 mL Centrifugal
Filtration Units, MilliporeSigma Corp., Burlington, MA). DFO-mIgG was prepared as previously
described with the following modifications: 500 µg (3.3 nmol) of mIgG and 8.4 µL of p-SCN-BnDFO was used.
3.2.4. Radiolabeling with 89Zr
590 µg of DFO-AR20.5 was diluted in 400 µL of Chelex PBS, pH 7.4. [89Zr]Zr-oxalate (1640
µCi) in 1.0 M oxalic acid was adjusted to pH 7.0-7.5 with 1.0 M Na2CO3, resulting in a total volume
of 95 µL. After the bubbling of CO2 ceased, the 89Zr solution was added to the antibody solution,
and the resulting mixture was placed on an agitating thermomixer at 500 rpm for 1 h at 25 °C. The
progress of the reaction was then assayed using radio-TLC with an eluent of 50 mM EDTA (pH
5). Subsequently, the reaction was quenched with 10 µL of 50 mM EDTA (pH 5), and the
immunoconjugate was purified using size exclusion chromatography (Sephadex G-25 M, PD-10
column, GE Healthcare; dead volume: 2.5 mL, eluted with 500 µL fractions of Chelex PBS, pH
7.4) and concentrated using centrifugal filtration units with a 50,000 Da molecular weight cut-off
(AmiconTM Ultra 2 mL Centrifugal Filtration Units, MilliporeSigma Corp., Burlington, MA). The
radiochemical purity of the final radiolabeled construct was assayed via radio-TLC using 50 mM
EDTA (pH 5) as an eluent. In the radio-TLC experiments, the radioimmunoconjugate remains at
the baseline, while free

89Zr4+

cations and [89Zr]-EDTA travel with the solvent front. For the

radiolabeling of DFO-mIgG, 340 µg of the construct and 950 µCi of [89Zr]Zr-oxalate (total volume
of 50 µL) was used.
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3.2.5. Cell Culture
Human ovarian cancer cell line SKOV3 was purchased from the American Type Culture
Collection (ATCC, Manassas, VA) and maintained in McCoy’s 5A Medium, supplemented with
10% heat-inactivated fetal calf serum, 100 units/mL penicillin, and 100 units/mL streptomycin in
an incubator (HeracellTM 150i, ThermoFisher Scientific) set to 37 °C and 5% CO2. Human ovarian
cancer cell line expressing the red-shifted firefly luciferase gene SKOV3-Red-FLuc was purchased
from PerkinElmer, Inc. (Waltham, MA) and maintained in McCoy’s 5A Medium, supplemented
with 10% heat-inactivated fetal calf serum. The cell lines were harvested and passaged upon
reaching 80% confluency using 0.25% trypsin/0.53 mM EDTA in Hank’s Buffered Salt Solution
without calcium and magnesium. All media was purchased from the Media Preparation Facility at
Memorial Sloan Kettering Cancer Center.
3.2.6. Flow Cytometry
The MUC1-expressing human ovarian cancer cell lines SKOV3 was used for flow cytometry
experiments. 50 µL of DFO-AR20.5 at 24, 12, 6, 3, 1.5, 0.75, 0.375, and 0.1875 µg/µL was
incubated with 1 x 106 cells/mL for 30 min on ice. The cells were washed with 1 mL of ice-cold
PBS three times by pelleting and resuspension. The cells were then incubated with 50 µL of a goat
anti-human IgG-AlexaFluor568 secondary antibody (ThermoFisher Scientific) at 8 µg/µL for 30
min on ice. Subsequently, the cells were again washed with ice-cold PBS and then analyzed on a
BD LSR II flow cytometer (BD Biosciences, San Jose, CA). Binding data was collected and then
plotted using FlowJoTM software (BD, Franklin Lakes, NJ).
3.2.7. Radiolabeled Antibody Stability Assays
The stability of the radioimmunoconjugate with respect to radiochemical purity and loss of
radioactivity from the antibody was investigated by incubating the antibody in human serum for 7
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days at 37 °C (n = 3) with shaking at 500 rpm. At predetermined times, the radiochemical purity
of the radiolabeled antibody was determined via radio-TLC with an eluent of 50 mM EDTA pH
5.0.
3.2.8. Xenograft Models
Six to eight-week-old female athymic nude mice were obtained from either Charles River
Laboratories (Wilmington, MA) or The Jackson Laboratory (Bar Harbor, ME) and allowed to
acclimatize for approximately 1 week prior to inoculation. Animals were housed in ventilated cages
and given water and food ad libitum.
Subcutaneous Xenograft Model: Mice were anaesthetized by inhalation of 2% isoflurane (Baxter
Healthcare, Deerfield, IL)/oxygen gas mixture and xenografted subcutaneously on the left shoulder
with 5 x 106 SKOV3 cells in a 150 µL cell suspension of a 1:1 mixture of fresh media: Matrigel
(Corning Life Sciences, Corning, NY). The SKOV3 tumors reached the ideal size for imaging and
biodistribution studies (~100-150 cm3) after approximately 6 weeks.
Orthotopic Xenograft Model: Mice were anaesthetized by inhalation of 1.5% isoflurane/oxygen
gas mixture, and surgery was performed on a heated surface to maintain body temperature. One
dose of meloxicam (2 mg/kg) and buprenorphine (0.5 mg/kg) was given preemptively via
subcutaneous injection. Bupivacaine, a local anesthetic agent, was injected into the tissue adjacent
to the incision line. The skin was then prepped for surgery by alternating scrubs of povidone-iodine
and 70% ethanol. A dorsolateral incision (1-2 cm in length) was made on the skin on the top right
of the spleen, and the retroperitoneum was dissected to expose the fat pad surrounding the ovary.
8 x 105 cells SKOV3-RedFluc in 15 µL of PBS were injected into the left ovary. The
retroperitoneum was closed using Vicryl sutures. The skin was closed with sterile wound clips and
the wound edges were sealed with a few drops of tissue adhesive. The tumors reached the ideal
size for experiments after approximately 10 weeks.
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To monitor tumor growth, mice were monitored using bioluminescence imaging at weeks 4 and
8. Approximately 5 min prior to bioluminescence imaging, mice were anesthetized by inhalation
of 2% isoflurane/oxygen gas mixture, administered 150 µL luciferin (PerkinElmer, Inc.) via
intraperitoneal injection, and placed on the scanner bed. Anesthesia was maintained by inhalation
of 1% isoflurane/oxygen gas mixture. Bioluminescent images were acquired with an IVIS
Spectrum Preclinical Imaging System (PerkinElmer). The resulting images were processing using
the Living Image (v4.4) software.
3.2.9. PET Imaging
PET imaging was conducted on a microPET Focus 120 small-animal scanner (Siemens Medical
Solutions, Malvern PA). Approximately 5 min prior to PET image acquisition, mice were
anaesthetized by inhalation of 2% isoflurane/oxygen gas mixture and kept under anesthesia for the
duration of the scan. Static scans were recorded at 24, 72, and 120 h after intravenous administration
of either [89Zr]Zr-AR20.5 or [89Zr]Zr-mIgG for a total scan time of 10 min. An energy window of
350-700 keV and a coincidence timing window of 6 ns were used. Data were sorted into 2dimensional histograms by Fourier re-binning, and transverse images were reconstructed by
filtered back-projection (FBP). The imaging data were then normalized to correct for nonuniformity of response of the detector, physical decay of the radioisotope to the time of injection,
dead-time count losses, and positron-branching ratio, but no attenuation, scatter, or partial-volume
averaging correction was applied. The counting rates in the reconstructed images were converted
to activity concentrations (percentage injected dose per gram of tissue [%ID/g]) using a system
calibration factor derived from the imaging of a mouse-sized water-equivalent phantom containing
89Zr.

Maximum intensity projection (MIP) images were generated from 3-dimensional ordered

subset expectation maximization reconstruction (3D-OSEM). The resulting images were analyzed
using ASIPro VMTM software (Concorde Microsystems).
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3.2.10. Acute Biodistribution
Athymic nude mice bearing subcutaneous SKOV3 (left shoulder, 100-150 mm3) were
randomized prior to the study and were warmed gently with a heat lamp for 5 min prior to the
administration of [89Zr]Zr-AR20.5 or [89Zr]Zr-mIgG via tail vein injection (t = 0). Subsequently,
the mice were euthanized via CO2(g) asphyxiation at 24, 72, and 120 h post-injection, and 13 tissues
(including tumor) were collected, rinsed in water, dried, weighed, and counted using a gamma
counter calibrated for 89Zr. Counts were converted into activity units (µCi) using a calibration curve
generated from known standards. The number of counts per minute in each tissue was background
and decay corrected to the injection time. The %ID/g for each sample was calculated by
normalization to the total injected activity.
3.2.11. Histopathology
The tumors and metastases harvested for the biodistribution were fixed in 10% neutral buffered
formalin and stored until the radioactivity decayed for 10 half-lives. The formalin-fixed tissue
samples were processed in ethanol and xylene, embedded in paraffin, sectioned into 5 µm thick
sections, and stained with hematoxylin and eosin (H&E). Sections from the tumors and metastases
were also stained by immunohistochemistry for MUC1 on a Leica Bond RX automated staining
platform (Leica Biosystems). Subsequently, heat-induced epitope retrieval was conducted in a pH
9.0 buffer, and the primary antibody (MUC1 antibody, ThermoFisher Scientific, MA532265) was
applied using a 1:250 dilution. Lastly, a polymer detection system (Novocastra Bond Polymer
Refine Detection, Leica Biosystems, DS9800) was applied. The resulting slides were interpreted
by a board-certified veterinary pathologist from the Laboratory of Comparative Pathology at
Memorial Sloan Kettering Cancer Center. The slides were digitized using Pannoramic Flash
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scanners (3DHistech). The scanned images were processed using Pannoramic Viewer software
(3DHistech).
3.3. Results
For the investigation at hand, AR20.5 was first modified with the desferrioxamine (DFO),
the ‘gold-standard’ chelator for the positron-emitting radiometal zirconium-89 (t1/2 ~ 3.3 d). To this
end, a commercially available isothiocyanate-bearing derivative of DFO ⎯ p-SCN-Bn-DFO ⎯

was appended to the antibody via the e-amines of solvent-exposed lysine residues, according to
published procedures (Figure 3.1).44 This approach to bioconjugation yielded an immunoconjugate
with an average of 1.2 ± 0.1 DFO/mAb as determined via MALDI-ToF analysis (Figures 3.2-3.3
and Table 3.1). Subsequently, the in vitro behavior of DFO-AR20.5 was evaluated via flow
cytometry. More specifically, these experiments confirmed the sensitive and specific binding of
DFO-AR20.5 to the MUC1 antigen on SKOV3 human ovarian cancer cells (Figure 3.4).

Figure 3.1. Schematic of the bioconjugation and radiosynthesis of [89Zr]Zr-DFO-AR20.5
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Figure 3.2. Representative MALDI-ToF spectrum for AR20.5.
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Figure 3.3. Representative MALDI-ToF spectrum for DFO-AR20.5.
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Constructs

Average mass (Da)

AR20.5

148716 ± 49

DFO-AR20.5

149652 ± 53

Degree of Labeling
(DFO/mAb)
1.2 ± 0.1

Table 3.1. Degree of labeling of DFO-AR20.5 as determined via MALDI-MS.

Figure 3.4. Flow cytometry analysis of DFO-AR20.5 with SKOV3 human ovarian cancer cells.
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Figure 3.5. Stability of [89Zr]Zr-DFO-AR20.5 in human serum at 37°C. Measurements were
collected using a radio-iTLC and performed in triplicate.
After confirming the antigen binding of DFO-AR20.5, the next step was to radiolabel the
immunoconjugate with zirconium-89, a radionuclide selected for the task due to the advantageous
match between its 3.3 d physical half-life and the multi-day circulation time of IgGs.45 Standard
published protocols were employed for the radiosynthesis, ultimately producing [ 89Zr]Zr-DFOAR20.5 in >99% radiochemical purity and a specific activity of 92.9 ± 10.0 MBq/mg (Figure
3.1).46 Finally, a stability study in human serum at 37 °C revealed that 98.3 ± 0.2% of [89Zr]ZrDFO-AR20.5 remains intact of an incubation period of 168 hours (Figure 3.5).
To evaluate the in vivo performance of our new probe, small animal PET imaging and
biodistribution studies were performed in athymic nude mice bearing subcutaneous SKOV3 human
ovarian cancer xenografts. PET images were obtained at 24, 72, and 120 h after the intravenous
administration of [89Zr]Zr-DFO-AR20.5 (6.9 – 7.5 MBq, 93 – 102 μg) or an isotype control
radioimmunoconjugate [89Zr]Zr-DFO-mIgG (6.9 – 7.1 MBq, 77 – 79 μg) via the tail vein. The PET
images reveal that [89Zr]Zr-DFO-AR20.5 clearly delineates the MUC1-expressing tumor, the
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tumoral activity concentrations of [89Zr]Zr-DFO-AR20.5 growing over the course of the 120 h
experiment (Figure 3.6, top). Furthermore, the minimal tumoral accumulation of the control
radioimmunoconjugate ⎯ [89Zr]Zr-DFO-mIgG ⎯ underscores that the uptake of [89Zr]Zr-DFOAR20.5 in the tumor is not predicated on the enhanced permeability and retention effect alone
(Figure 3.6, bottom).

Figure 3.6. Planar (left) and maximum intensity projection (right; scaled to a minimum of 0% and
a maximum of 100%) PET images of athymic nude mice bearing subcutaneous SKOV3 xenografts
at 24, 72, and 120 h following the intravenous tail-vein injection of [89Zr]Zr-DFO-AR20.5 (6.9 –
7.5 MBq; 186 – 204 μCi; in 200 μL 0.9% sterile saline) or [89Zr]Zr-DFO-mIgG (6.9 – 7.1 MBq,
187 – 192 μCi). The white arrows mark the tumors.
All of these observations are supported by the biodistribution results. More specifically, the
tumoral activity concentrations of [89Zr]Zr-DFO-AR20.5 grew throughout the study, from 11.8 ±
4.1 %ID/g at 24 h post-injection to 22.3 ± 4.6 %ID/g at 72 h p.i. to 33.4 ± 11.2 %ID/g at 120 h p.i
(Figure 3.7 and Table 3.2). A blocking experiment in which the tumor-bearing mice are
administered a mixture of [89Zr]Zr-DFO-AR20.5 and a vast excess (500 g) of unlabeled AR20.5
effectively demonstrated the specificity of the former for the MUC1-expressing ovarian cancer
cells: the tumoral activity concentration was 6.9 ± 2.5 %ID/g with blocking versus 22.3 ± 4.6 %ID/g
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without (P = 0.0006; Figure 3.7 and Table 3.2). The biodistribution data also reveals that the
background activity concentration in the blood decreases from 15.5 ± 2.9 %ID/g at 24 h p.i. to 9.2
± 0.6 %ID/g at 120 h p.i, as is typical for radioimmunoconjugates. In contrast, the activity
concentrations in the bone increase slightly over the course of the experiment ⎯ from 4.8 ± 1.8
%ID/g at 24 h p.i. to 6.6 ± 3.0 %ID/g at 120 h p.i ⎯ in another phenomenon frequently observed
with

89Zr-labeled

antibodies. The activity concentrations in other healthy organs – including the

liver, spleen, and kidneys – remain fairly constant in the range of 2-7% ID/g throughout. While
MUC1 is expressed on the cell surface, the antigen can be shed into circulation as well, whereupon
the formation of immune complexes with [89Zr]Zr-DFO-AR20.5 may contribute to high retention
in circulation and high liver and spleen uptake. Taken together, these biodistribution data yields
generally favorable ⎯ though admittedly not extraordinary ⎯ tumor-to-healthy organ activity
concentration ratios.
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Figure 3.7. Biodistribution data from athymic nude mice (n = 5 per time point) bearing SKOV3
human ovarian cancer xenografts collected 24, 72, and 120 h after the intravenous administration
of [89Zr]Zr-DFO-AR20.5 (0.65 – 0.69 MBq; 17.6 – 18.6 μCi; 6.6 – 7.0 μg). For the 72 h blocking
experiment, the mice were administered the same amount of [89Zr]Zr-DFO-AR20.5 mixed with a
excess of unmodified AR20.5 (~500 μg per mouse).
24 h

72 h

72 h block

120 h

Blood

15.5 ± 2.9

11.9 ± 2.9

9.8 ± 2.9

9.2 ± 0.6

Tumor

11.8 ± 4.1

22.3 ± 4.6

6.9 ± 2.5

33.4 ± 11.2

Heart

4.2 ± 1.1

3.2 ± 0.7

3.0 ± 0.8

2.7 ± 0.2

Lungs

8.3 ± 1.9

5.8 ± 2.1

5.3 ± 1.9

4.6 ± 0.3

Liver

6.5 ± 1.6

6.0 ± 1.1

5.6 ± 2.3

6.2 ± 1.1

Spleen

4.5 ± 1.0

4.7 ± 1.6

3.5 ± 1.1

4.8 ± 0.7

Stomach

1.0 ± 0.3

1.0 ± 0.3

0.8 ± 0.3

0.9 ± 0.2

Small Intestine

1.8 ± 0.2

1.4 ± 0.4

1.1 ± 0.3

1.2 ± 0.2

Large Intestine

1.2 ± 0.1

0.9 ± 0.3

0.7 ± 0.2

0.8 ± 0.2

Kidneys

6.7 ± 2.9

4.6 ± 1.1

4.9 ± 1.1

4.4 ± 0.3

Muscle

1.3 ± 0.2

0.9 ± 0.2

0.9 ± 0.3

0.8 ± 0.1

Bone

2.4 ± 0.4

3.7 ± 0.9

3.3 ± 0.7

5.0 ± 1.5

Table 3.2. Biodistribution data from athymic nude mice (n = 5 per time point) bearing SKOV3
human ovarian cancer xenografts collected 24, 72, and 120 h after the intravenous administration
of [89Zr]Zr-DFO-AR20.5 (0.65 – 0.69 MBq; 17.6 – 18.6 μCi; 6.6 – 7.0 μg). For the 72 h blocking
experiment, the mice were administered the same amount of [89Zr]Zr-DFO-AR20.5 mixed with a
excess of unmodified AR20.5 (~500 μg per mouse). The values are %ID/g ± SD. Stomach, small
intestine, and large intestine values include contents.
With the subcutaneous xenograft data in hand, the next step was to evaluate [89Zr]Zr-DFOAR20.5 in a more realistic orthotopic xenograft model. To this end, orthotopic human ovarian
cancer xenografts were established in athymic nude mice via the injection of MUC1- and
luciferase-expressing SKOV3-RedFluc cells into the fat pad surrounding the ovary. As early as 24
h, the xenograft in the left ovary can be clearly seen in the PET images, and the uptake in the tumor
increases throughout the experiment (Figure 3.8). As in the experiments with the subcutaneous
xenograft model, PET imaging using an isotype control radioimmunoconjugate ⎯ [89Zr]Zr-DFO-
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mIgG ⎯ revealed little tumoral accumulation, reinforcing the specificity of the MUC1-targeting
imaging agent. In this case, the biodistribution data is again consistent with the imaging results,
revealing a tumoral activity concentration of 11.3 ± 7.1 %ID/g at 120 p.i. but also significant
accumulation of [89Zr]Zr-DFO-AR20.5 in the liver (10.5 ± 2.4 %ID/g) and spleen (4.5 ± 1.6 %ID/g)
as well (Figure 3.8 and Table 3.3). The latter is most likely the result of the formation of immune
complexes between shed MUC1 and circulating radioimmunoconjugate that were subsequently
deposited in the liver and spleen. Interestingly, focal uptake of [89Zr]Zr-DFO-AR20.5 was also
observed in several lesions that appeared to be metastases in abdomen, peritoneum, liver, and right
ovary of the orthotopic tumor-bearing mice (Figure 3.9). Histopathological analyses revealed that
these lesions were composed of neoplastic cells arranged in solid nests and scattered tubules and
confirmed them to be ovarian cell carcinoma (Figure 3.8). Furthermore, immunohistochemical
staining revealed that that the metastatic cells do, indeed, express MUC1, explaining their uptake
of the radioimmunoconjugate (Figure 3.8).

Figure 3.8. (A) Bioluminescence (left), planar (center) and maximum intensity projection (right;
scaled to a minimum of 30% and maximum of 100%) PET images of athymic nude mice bearing
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orthotopic SKOV3-Red-FLuc xenografts at 24, 72, and 120 h following the intravenous tail-vein
injection of [89Zr]Zr-DFO-AR20.5 (5.6 – 6.0 MBq, 150.6 – 161.4 μCi, 59.1 – 63.3 μg; in 200 μL
0.9% sterile saline) or [89Zr]Zr-DFO-mIgG (6.1 – 6.4 MBq, 163.7 – 171.7 μCi, 61.5 – 70.1 μg).
The white arrows mark the tumors; (B) Planar PET image of the representative athymic nude mouse
bearing an orthotopic SKOV3-Red-FLuc xenograft at 120 hours post-injection of [89Zr]Zr-DFOAR20.5 (5.6 – 6.0 MBq, 150.6 – 161.4 μCi, 59.1 – 63.3 μg; in 200 μL 0.9% sterile saline). The
white arrows mark the tumor (T) and peritoneal metastatic lesion (Met); (C) H&E (10x magnified;
left) and IHC (10x magnified; right) staining of the peritoneal metastatic lesion from the
representative mouse, with brown staining indicating the expression of MUC1.

Blood
Tumor
Heart
Lungs
Liver
Spleen
Stomach
Small Intestine
Large Intestine
Kidneys
Muscle
Bone

[89Zr]Zr-DFO-AR20.5
2.4 ± 2.1
11.3 ± 7.1
0.9 ± 0.7
1.5 ± 1.4
10.5 ± 2.4
6.1 ± 0.3
0.3 ± 0.1
0.4 ± 0.1
0.4 ± 0.3
2.1 ± 0.4
0.5 ± 0.2
1.7 ± 0.2

[89Zr]Zr-DFO-mIgG
4.2 ± 1.1
3.1 ± 0.8
1.2 ± 0.2
1.9 ±0.6
5.1 ± 0.1
4.5 ± 1.6
0.3 ± 0.1
0.5 ± 0.2
0.5 ± 0.1
5.2 ± 0.5
0.6 ± 0.2
1.8 ± 0.4

Table 3.3. Biodistribution data from athymic nude mice bearing SKOV3-RFluc human ovarian
cancer orthotopic xenografts collected 120 h after the intravenous administration of [89Zr]Zr-DFOAR20.5 (5.6 – 6.0 MBq; 150.6 – 161.4 μCi; 59.1 – 63.3 μg; n = 3) or [89Zr]Zr-DFO-mIgG (6.1 –
6.4 MBq; 163.7 – 171.7 μCi; 61.5 – 70.1 μg; n = 3) via the tail vein. The values are %ID/g ± SD,
and the stomach, small intestine, and large intestine values include contents.

Figure 3.9. (A) Biodistribution data for athymic nude mice bearing orthotopic SKOV3-Red-FLuc
xenografts collected 120 h following the intravenous tail-vein injection of [89Zr]Zr-DFO-AR20.5
(5.6 – 6.0 MBq, 150.6 – 161.4 μCi, 59.1 – 63.3 μg; in 200 μL 0.9% sterile saline); (B) Planar (left)
and maximum intensity projection (MIP, right) PET images of a representative athymic nude
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mouse bearing an orthotopic SKOV3-Red-FLuc xenograft at 120 hours post-injection of [89Zr]ZrDFO-AR20.5 (5.6 – 6.0 MBq, 150.6 – 161.4 μCi, 59.1 – 63.3 μg; in 200 μL 0.9% sterile saline);
(C) Biodistribution data for the metastatic lesions collected from the orthotopic tumor-bearing
mice.
3.4. Discussion
In the preceding pages, we have described the synthesis, characterization, and in vivo evaluation
of [89Zr]Zr-DFO-AR20.5, a radioimmunoconjugate for the PET imaging of MUC1-expressing
tumors. The chemical and biological characterization experiments clearly demonstrate that the
bioconjugation and radiolabeling of AR20.5 did not adversely affect the ability of the antibody to
bind its target antigen. Moving on to the in vivo experiments, the data show that [89Zr]Zr-DFOAR20.5 is capable of clearly visualizing MUC1-expressing tumor tissue in mice bearing both
subcutaneous and orthotopic ovarian cancer xenografts. With respect to the former, the in vivo
behavior of [89Zr]Zr-DFO-AR20.5 in mice bearing MUC1-positive orthotopic ovarian cancer
xenografts mirrors that of other

89Zr-labeled

radioimmunoconjugates. To wit, while the activity

concentration in tumor tissue increased over the course of the experiment, that in the blood and
several other well-perfused organs (e.g. the lungs) decreased in kind. A small amount of
radioactivity was observed in the bones of the mice, likely the result of the in vivo demetallation of
the radioimmunoconjugate and the subsequent deposition of the osteophilic [89Zr]Zr4+ in the bone.
While the tumor-to-muscle activity concentration ratios in these mice were quite high (42.7 ±
14.6 at 120 h p.i.), several key tumor-to-healthy organ activity concentration ratios ⎯ most notably
tumor-to-blood (3.6 ± 1.2 at 120 h p.i.), tumor-to-liver (5.4 ± 2.0 at 120 h p.i.), and tumor-to-spleen
(6.9 ± 2.5 at 120 h p.i.) ⎯ lie below the impressive, ‘double digit’ values observed for several other
89Zr-labeled

radioimmunoconjugates such a [89Zr]Zr-DFO-J591, [89Zr]Zr-DFO-trastuzumab, and

[89Zr]Zr-DFO-pertuzumab. This phenomenon is most likely related to the shedding of MUC1 and
the formation of MUC1-[89Zr]Zr-DFO-AR20.5 immune complexes that can persist in the blood
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and subsequently accumulate in the liver and spleen. However, our previous preclinical data with
the CA125-targteted radioimmunoconjugate [89Zr]Zr-DFO-B43.13 as well as the preclinical and
clinical performance of the CA19.9-targeted radioimmunoconjugate [89Zr]Zr-DFO-5B1 reinforce
the feasibility of the immunoPET imaging of shed antigens.33,

47, 48

Furthermore, the in vivo

performance of [89Zr]Zr-DFO-AR20.5 compares favorably to that of two recently reported MUC1targeted radioimmunoconjugates: [64Cu]Cu-DOTA-PR81 and [89Zr]Zr-DFO-GGSK-1/30.38,

43

While direct comparisons are ⎯ of course ⎯ dubious due to the use of different tumor models, the
tumoral activity concentrations and tumor-to-healthy organ activity concentration ratios of
[89Zr]Zr-DFO-AR20.5 exceeded those created by the former and were roughly equivalent to those
produced by the latter. Finally, the in vivo data in mice bearing orthotopic xenografts largely
reflects the data collected in the subcutaneous tumor-bearing animals. However, the ability of
[89Zr]Zr-DFO-AR20.5 to visualize several abdominal, peritoneal, hepatic, and ovarian metastatic
lesions underscores its potential as a tool for the non-invasive staging of the disease.
3.5. Conclusion
Moving forward, we plan to continue to explore the use of [89Zr]Zr-DFO-AR20.5 for both
diagnostic and theranostic imaging in ovarian cancer. Along these lines, we are currently
formulating plans to explore the in vivo performance of [89Zr]Zr-DFO-AR20.5 in mice bearing
patient-derived ovarian cancer xenografts. Furthermore, we plan to interrogate the utility of
[89Zr]Zr-DFO-AR20.5 as a predictive theranostic imaging agent in human MUC1 transgenic mice
(MUC.Tg) undergoing AR20.5/anti-PD-L1/PolyICLC combination therapy. Finally, we have also
begun exploring whether the in vivo performance of [89Zr]Zr-DFO-AR20.5 could benefit from the
removal of the heavy chain glycans ⎯ and thus the abrogation of the radioimmunoconjugate’s
interactions with murine FcRI receptors ⎯ a phenomenon that we have previously observed and
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studied. In this case, we believe that the modulation of the interactions between [ 89Zr]Zr-DFOAR20.5 and the murine immune system may be particularly important given the therapeutic
mechanism of the antibody. In the end, this pilot investigation has clearly demonstrated that
[89Zr]Zr-DFO-AR20.5 is an effective tool for the non-invasive delineation of MUC1-expressing
tumor tissue, and we are hopeful that in the future, this radioimmunoconjugate can play an
important role in the clinical diagnostic and theranostic imaging of ovarian cancer.
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Chapter 4 : A Molecularly-Targeted Intraoperative Imaging Agent
for High-Grade Serous Ovarian Cancer
This chapter is an adaptation of unpublished work from Fung, K.; Sharma, S. K.; Keinänen, O.;
Lewis, J. S.; Zeglis, B. M. A Molecularly-Targeted Intraoperative Imaging Agent for High-Grade
Serous Ovarian Cancer.
4.1. Introduction
Ovarian cancer is the most lethal gynecologic malignancy and the fifth leading cause of
cancer-related deaths in women.1 Cytoreductive surgery (CRS) remains the most effective firstline treatment for this disease. However, the complete removal of malignant tissue during surgery
can be extremely challenging. In patients with unresectable disease, neoadjuvant chemotherapy
followed by interval CRS is a valid alternative to primary CRS and is supported by multicenter
randomized controlled trials.2, 3 Indeed, the volume of residual disease (RD) after CRS is one of
the strongest prognostic indicators of progression-free and overall survival in ovarian cancer
patients.4 While optimal CRS is defined as RD <1cm, each incremental decrease in RD below 1
cm improves outcomes.2, 3 In spite of this, the determination of RD is based solely on the surgeon’s
visual and manual assessment. The limitations of this approach are underscored by a study that
discovered high inter-observer variability, with surgeons more often underestimating rather than
overestimating the amount of RD.5 Furthermore, several studies have examined the value of
postoperative CT and found that anatomical imaging revealed RD >1 cm in up to 40% of patients
that had been deemed ‘optimally resected’.6, 7 Collectively, this makes a clear case for the need to
improve the intraoperative assessment of RD in the treatment of ovarian cancer patients. Therefore,
the development of tools that can improve the assessment of RD during CRS is a vitally important
unmet clinical need. The development of this technology could aid clinicians in achieving greater
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reduction of disease burden via NIRF-guided resection of residual tumors to improve patient
outcomes.
High-grade serous ovarian cancer (HGSOC) comprises the vast majority (~70%) of ovarian
adenocarcinomas.8 A vital molecular signature of this malignant histotype is the over-expression
of MUC16, a mucinous glycoprotein that carries the Cancer Antigen 125 (CA125) epitope. 9, 10 A
common telltale sign of ovarian cancer is elevated serum CA125 levels, and malignant cells
themselves are known to profusely express this tumor-associated antigen to their advantage.11
Despite being a shed antigen, high concentrations of MUC16/CA125 remain on the surface of
cancer cells, enabling the imaging of ovarian cancer.12 A CA125-targeted intraoperative imaging
agent could thus be a valuable surgical tool for the identification of microscopic or metastatic
deposits within the peritoneum and in clinically normal-appearing lymph nodes.
Over the past three years, our team has been at the forefront of the development and
preclinical validation of various MUC16-targeted molecular imaging agents.13,

14

We recently

reported the creation of a PET imaging agent for the in vivo delineation of CA125 expression in
ovarian cancer based on the CA125- targeting B43.13 antibody.15 The CA125-targeting murine
antibody at the center of this proposal — B43.13 (K D for CA125 = 1.2 nM) — has already been
the subject of clinical trials as a cancer vaccine as well as a vector for immunoscintigraphy in
ovarian cancer patients.16-22 Furthermore, B43.13-based radioimmunoconjugates labeled with 64Cu
and

89Zr

have shown significant potential for the PET imaging of CA125 expression in murine

models of ovarian cancer.12, 23 In vivo imaging experiments in murine xenograft models of HGSOC
clearly demonstrate that this imaging agent is not only capable of visualizing primary tumor tissue
but also provides sensitive maps of the metastatic spread of ovarian cancer through the ipsilateral
chain of lymph nodes.23
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Herein, we synthesized a B43.13-based immunoconjugate labeled with the near-infrared
dye – IRDye800CW (IR800) for NIRF imaging of HGSOC during CRS. Subsequently, we
characterized the ability of B43.13-IR800 to bind to CA125-expressing OVCAR3 human ovarian
cancer cells, evaluated their in vivo performance in subcutaneous, orthotopic, and patient-derived
xenograft mouse models of HGSOC, and performed ex vivo histopathology analysis. In the short
term, this work could have a tremendous impact on patient outcomes by helping clinicians to better
assess the peritoneum for residual disease and thereby facilitate a more complete resection of
malignant tissue during CRS. In the long term, we believe that this work could help usher in a new
era for imaging within the operating room to ultimately improve the surgical treatment of a wide
variety of tumors.
4.2. Experimental
4.2.1. Materials and Methods
Unless otherwise noted, all chemicals were purchased from Sigma-Aldrich (St. Louis, MO)
or Fisher Scientific (Pittsburgh, PA) and were used without further purification. All water used was
ultrapure (>18.2 MΩcm-1 at 25 °C), and dimethylsulfoxide was of molecular biology grade
(>99.9%). IRDye® 800CW NHS ester and IRDye® 800CW DBCO was purchased from LI-COR
Biosciences (Lincoln, Nebraska). The B43.13 antibody was obtained from Oncoquest, Inc.
(Edmonton, Alberta), and mouse immunoglobulin G (mIgG) was purchased from Thermo Fisher
Scientific (Waltham, MA). All in vivo experiments were performed in accordance with published
protocols approved by the Institutional Animal Care and Use Committees of Hunter College, Weill
Cornell Medical College, and Memorial Sloan Kettering Cancer Center.
4.2.2. Synthesis of nssB43.13-IR800 and nssmIgG-IR800
B43.13 (1.5 mg, 10.03 nmol) was dissolved in 100 µL of phosphate-buffered saline (PBS,
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pH 7.4), and the pH of the solution was adjusted to 8.8-9.0 with Na2CO3 (0.1 M). 2 equivalents of
IRDye® 800CW NHS Ester (4 µL, 5.9 mg/mL in DMSO) was added to the solution in small
aliquots. The resulting solution was incubated at 37°C for 1 hour with shaking at 500 rpm. The
IR800CW-modified antibody was then purified using size exclusion chromatography (Sephadex
G-25 M, PD-10 column, GE Healthcare; dead volume: 2.5 mL, eluted with 2 mL of Chelex PBS,
pH 7.4) and concentrated using centrifugal filtration units with a 50,000 Da molecular weight cutoff (AmiconTM Ultra 2 mL Centrifugal Filtration Units, MilliporeSigma Corp., Burlington, MA).
nssmIgG-IR800CW

was prepared as previously described, except 6 equivalents of IR800CW (11.9

µL) was used instead. To determine the degree of labeling (DOL), UV-Vis measurements were
obtained using a Shimadzu BioSpec-Nano Micro-Volume UV-Vis Spectrophotometer (Shimadzu,
Kyoto, Japan). Absorbance measurements were taken at 280 nm and 774 nm, and the DOL was
calculated using the following formulas:
AmAb = A280 – Amax(CF)
DOL = [Amax*MWmAb]/[[mAb]*εIR800CW]]
where the correction factor (CF) for IR800CW is 0.03 as provided by the supplier, MWmAb =
150,000 Da, εIR800CW = 240,000 cm-1M-1, and ε280, mAb = 210,000 cm-1M-1.
4.2.3. Synthesis of ssB43.13-IR800
Glycans Modification: For the deglycosylation of B43.13, B43.13 (4.5 mg) was combined
with 1.5 units of recombinant EndoS enzyme (New England BioLabs, Ipswich, MA) per 1 µg of
antibody, 50 µL 500 mM sodium phosphate, pH 7.5 (10X Glycobuffer 1 from New England
Biolabs), and H2O to make up a total reaction volume of 500 µL. The reaction was incubated at
37°C for 24 h and then purified using magnetic chitin beads (New England Biolabs). The
deglycosylated B43.13 antibody was buffer exchanged into pre-treatment (50 mM Bis-Tris, 100
mM NaCl, pH 6.0) using a centrifugal filter (AmiconTM Ultra 2 mL Centrifugal Filtration Units,
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MilliporeSigma Corp., Burlington, MA). To perform the buffer exchange, the filter was first
equilibrated with 50 mM Bis-Tris, pH 6.0 and then centrifuged for 6 minutes at 5,000 g. After the
final spin, the deglycosylated antibody was isolated in 100 µL (22.58 mg/mL).
GalNAz Labeling: After the EndoS treatment and buffer exchange, 75 μL H2O, 15 μL 1M Tris
buffer pH 7.6, 2.5 μL 1M MnCl2, 5.3 μL UDP-GalNAz (from a stock solution at 40 mM in H 2O)
and 13.2 μL Gal-T1(Y289L) (stock solution at 2 mg/mL) were added to the reaction solution for a
final volume of 265 μL. This resultant solution contained final concentrations of 13.12 mg/mL
antibody, 9.5 mM MnCl2, 0.8 mM UDP-GalNAz, and 0.1 mg/mL Gal-T1(Y289L) and was
incubated overnight at 30°C.
DBCO-IR800 Ligation: After the GalNAz labeling step, the resulting solution was purified via
centrifugal filtration using 2 mL Amicon filtration units and tris-buffered saline (TBS, pH 7.4).
After centrifugation, the modified B43.13 (2 sets of 1,613 μg in 88 μL of TBS) was combined with
86.0 μL DBCO-IR800 each (2 mM stock solution, LI-COR Biosciences) and TBS (pH 7.4) to yield
solutions with a final volume of 1.5 mL containing 1.08 mg/mL B43.13 and 0.1 mM DBCO. The
solutions were incubated overnight at 25°C.
Purification: After labeling the antibody with DBCO-IR800, the site-specifically modified
antibody was purified via size exclusion chromatography (PD-10 column, GE Healthcare) and
concentrated using centrifugal filtration units with a 50,000 Da molecular weight cut off
(AmiconTM Ultra 2 mL Centrifugal Filtration Units, MilliporeSigma Corp., Burlington, MA) and
PBS (pH 7.4).
4.2.4. Cell Culture
Human ovarian cancer cell line SKOV3 was purchased from the American Type Culture
Collection (ATCC, Manassas, VA) and maintained in McCoy’s 5A Medium, supplemented with
10% heat-inactivated fetal calf serum, 100 units/mL penicillin, and 100 units/mL streptomycin in
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an incubator (HeracellTM 150i, ThermoFisher Scientific) set to 37 °C and 5% CO2. Human ovarian
cancer cell OVCAR3 was purchased from the ATCC and maintained in RPMI 1640 Medium,
supplemented with heat inactivated fetal bovine serum (20% v/v), 2 mM L-glutamine, 10 mM
HEPES, 1 mM sodium pyruvate, 4.5 g/L glucose, 1.5 g/L sodium bicarbonate, 0.01 mg/mL bovine
insulin (Gemini Bio-Products, 700-112P), 100 units/mL penicillin, and 100 units/mL streptomycin.
The cell lines were harvested and passaged upon reaching 80% confluency using 0.25%
trypsin/0.53 mM EDTA in Hank’s Buffered Salt Solution without calcium and magnesium. All
media was purchased from the Media Preparation Facility at Memorial Sloan Kettering Cancer
Center.
4.2.5. Flow Cytometry
Flow cytometry experiments were performed with two cell lines, CA125-positive OVCAR3
and CA125-negative SKOV3 human ovarian cancer cells. Either 106 OVCAR3 or SKOV3 cells
were incubated with 1 µg/mL, 4 µg/mL, 8 µg/mL, and 16 µg/mL

ssB43.13-AF488

immunoconjugate for 30 min on ice. A blocking condition was also created by incubating the
OVCAR3 or SKOV3 cells with 2 µg/mL ssB43.13-AF488 and a 75-fold excess of unmodified
B43.13 (150 µg/mL). Cells were washed by pelleting, resuspension, and analyzed on a BD LSR II
(BD Biosciences, San Jose, CA). Binding data was collected in triplicate, averaged, and plotted.
4.2.6. Xenograft Models
Ten to twelve-week-old female NSG mice were obtained from The Jackson Laboratory
(Bar Harbor, ME) and allowed to acclimatize for approximately 1 week prior to inoculation.
Animals were housed in ventilated cages and given water and food ad libitum.
Subcutaneous Xenograft: Mice were anaesthetized by inhalation of 2% isoflurane (Baxter
Healthcare, Deerfield, IL)/oxygen gas mixture and xenografted subcutaneously on the right
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shoulder with 5 x 106 OVCAR3 cells in a 150 µL cell suspension of a 1:1 mixture of fresh media:
Matrigel (Corning Life Sciences, Corning, NY). The OVCAR3 tumors reached the ideal size for
imaging and biodistribution studies (~200-300 cm3) after approximately 4 weeks.
Orthotopic Xenograft: Mice were anaesthetized by inhalation of 1.5% isoflurane/oxygen gas
mixture, and surgery was performed on a heated surface to maintain body temperature. One dose
of meloxicam (2 mg/kg) and buprenorphine (0.5 mg/kg) was given preemptively via subcutaneous
injection. Bupivacaine, a local anesthetic agent, was injected into the tissue adjacent to the incision
line. The skin was then prepped for surgery by alternating scrubs of povidone-iodine and 70%
ethanol. A dorsolateral incision (1-2 cm in length) was made on the skin on the top right of the
spleen, and the retroperitoneum was dissected to expose the fat pad surrounding the ovary. 3 x 106
cells OVCAR3-Luc in 15 µL of PBS were injected into the left ovary. The retroperitoneum was
closed using Vicryl sutures. The skin was closed with sterile wound clips and the wound edges
were sealed with a few drops of tissue adhesive. The tumors reached the ideal size for experiments
after approximately 8 weeks.
Patient-derived Xenograft (PDX): The PDX seed was revived from frozen stocks and xenografted
subcutaneously on the right shoulder. The tumors reached the ideal size for experiments after
approximately 4 weeks.
4.2.7. NIRF Imaging
The IR800-labeled immunoconjugate was administered 72 h prior the NIRF imaging.
Approximately 5 min prior to imaging, mice were anesthetized by inhalation of 2%
isoflurane/oxygen gas mixture and placed on the scanner bed. Anesthesia was maintained by
inhalation of 1% isoflurane/oxygen gas mixture. Fluorescent images were acquired with an IVIS
Spectrum Preclinical Imaging System (PerkinElmer) using an excitation wavelength of 740 nm and
emission wavelength of 820 nm. For ex vivo imaging, the mice were sacrificed via CO2
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asphyxiation. Select tissues (including tumor) were collected, rinsed in water, dried, and placed on
either a black sheet of paper or petri dish. Fluorescent images were acquired with the same
wavelength settings on the IVIS Spectrum. The resulting images were processing using the Living
Image (v4.4) software.
4.2.8. Histopathology
The tumors and metastases harvested for the biodistribution were fixed in 10% neutral
buffered formalin. The formalin-fixed tissue samples were processed in ethanol and xylene,
embedded in paraffin, sectioned into 5 µm thick sections, and stained with hematoxylin and eosin
(H&E). Sections from the tumors and metastases were also stained by immunohistochemistry for
MUC16/CA125 on a Leica Bond RX automated staining platform (Leica Biosystems).
Subsequently, heat-induced epitope retrieval was conducted in a pH 9.0 buffer, and the primary
antibody (Novus Biologicals, NBP1-96619) was applied using a 1:250 dilution. This was followed
by applying a polymer detection system (Novocastra Bond Polymer Refine Detection, Leica
Biosystems, DS9800). The resulting slides were interpreted by a board-certified veterinary
pathologist from the Laboratory of Comparative Pathology at Memorial Sloan Kettering Cancer
Center. The slides were digitized using Pannoramic Flash scanners (3DHistech). The scanned
images were processed using Pannoramic Viewer software (3DHistech).
4.3. Results and Discussion
4.3.1. PET Imaging of CA125 Expression in Ovarian Cancer
We have recently reported the synthesis, characterization, and in vivo preclinical validation of
[89Zr]Zr-DFO-B43.13, a CA125-targeted radioimmunoconjugate for the PET imaging of CA125positive ovarian cancer. B43.13 was conjugated to desferrioxamine (DFO) using p-SCN-Bn-DFO,
and the resulting immunoconjugate was radiolabeled with [89Zr]Zr4+ to create a [89Zr]Zr-DFO-
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B43.13 radioimmunoconjugate that was shown to have high radionuclidic purity (>99%), specific
activity (5.5  0.8 mCi/mg), and immunoreactivity (>92%).
Preclinical experiments in murine models of ovarian cancer clearly demonstrate that [89Zr]ZrDFO-B43.13 is a highly effective imaging agent for the non-invasive visualization of CA125expressing tissues. PET imaging experiments in athymic nude mice bearing bilateral OVCAR3
(CA125+) and SKOV3 (CA125-) human ovarian cancer xenografts illustrated the selectivity of the
radiotracer. While high activity concentrations were observed in the CA125-positive OVCAR3
xenografts, only low levels of uptake were seen in the CA125-negative SKOV3 tumors. Followup imaging and biodistribution experiments in mice bearing only OVCAR3 xenografts revealed
activity concentrations in the tumor and blood of 24.7  7.5 %ID/g and 4.0  3.0 %ID/g,
respectively, at 120 h post-injection (Figure 4.1). The non-target organ with the highest activity
concentration was the liver, with approximately 15 %ID/g at all time points. All other organs ⎯
including the ovaries ⎯ displayed activity concentrations <5 %ID/g.

Figure 4.1. CA125-targeted PET imaging with 89Zr-DFO-B43.13. Serial PET images of an
athymic nude mouse bearing a CA125-positive OVCAR3 xenograft after the administration of
89Zr-DFO-B43.13 via tail vein injection. The coronal planar images intersect the middle of the
tumor; T = tumor; L = liver; LN = lymph node.
Easily the most intriguing facet of the in vivo experiments with

89Zr-DFO-B43.13

was the

revelation of the radiotracer’s ability to track the metastatic spread of the disease through the
ipsilateral lymph node chain. In mice bearing OVCAR3 xenografts, high activity concentrations
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were observed in the axillary (104.8  45.1 %ID/g at 72 h p.i.) and brachial (56.6  39.4 %ID/g at
72 h p.i.) lymph nodes proximal to the tumor. In these same mice, the corresponding contralateral
lymph nodes displayed far lower uptake of the radioimmunoconjugate: 3.7  3.2 %ID/g (axillary)
and 6.4  3.7 %ID/g (brachial). Furthermore, in a subset of mice, high activity concentrations were
observed in the ipsilateral sub-mandibular lymph node — but not the corresponding contralateral
node (Figures 4.2-4.4). Control experiments using a

89Zr-labeled

isotope IgG revealed minimal

uptake in all ipsilateral and contralateral nodes (Figure 4.4).

Figure 4.2. The visualization of lymph nodes with 89Zr-DFO-B43.13. Coronal PET images (120
h p.i) of three OVCAR3 tumor-bearing mice demonstrating the uptake of the
radioimmunoconjugate in the ipsilateral chain of lymph nodes. T = tumor; ALN = axillary lymph
nodes; BLN = brachial lymph nodes; SMLN = sub-mandibular lymph nodes; L = liver.

Figure 4.3. The visualization of lymph nodes with 89Zr-DFO-B43.13. Coronal (A) and
maximum intensity projection (B) PET images obtained 72 h after the administration of 89Zr-DFOB43.13 to a mouse bearing a CA125-positive OVCAR3 xenograft; (C) PET/CT image obtained
120 h after the administration of 89Zr-DFO-B43.13 to the same mouse; T = tumor; ALN = axillary
lymph nodes; BLN = brachial lymph node; SMLN = sub-mandibular lymph node; L = liver.
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Figure 4.4. Comparative analysis of activity concentrations from 89Zr-DFO-B43.13 vs. 89ZrDFO-Isotype IgG in select tissues of interest. Biodistribution of 89Zr-DFO-B43.13 and 89ZrDFO-Isotype IgG in OVCAR3 xenograft-bearing mice (n = 4 per group) comparing the activity
concentrations of the two radioimmunoconjugates in the tumor, relevant lymph nodes, and liver.
*Indicates p value < 0.05.
Ex vivo histopathological analyses of the resected lymph nodes clearly confirmed the presence
of metastatic disease in the ipsilateral nodes. The contralateral nodes, on the other hand, appeared
normal. More specifically, in mice displaying high concentrations of activity in the ipsilateral
axillary and brachial nodes but not the ipsilateral submandibular node, it was found that the axillary
and brachial nodes showed evidence of metastatic spread while the submandibular node did not.
However, in mice displaying high activity concentrations in all three ipsilateral lymph nodes,
evidence of metastases was found in the ipsilateral submandibular node as well (Figure 4.5). The
correlation between the histopathology and PET imaging was remarkable: lymph nodes delineated
in the PET scans were pathologically confirmed to contain metastatic disease, while lymph nodes
not visualized via PET were proven negative for the presence of ovarian cancer. Simply put, neither
false negatives nor false positives were observed.
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Figure 4.5. Histopathological analysis of contralateral and ipsilateral sub-mandibular lymph
nodes. (O) Magnified coronal PET image of the primary OVCAR3 tumor, ipsilateral lymph nodes,
and contralateral lymph nodes of a mouse injected with 89Zr-DFO-B43.13; (A) 20X- and (B) 10Xmagnified images of H&E-stained sections of the PET-negative sub-mandibular lymph node; (C)
20X- and (D) 10X-magnified images of the same lymph node, analyzed by IHC staining for CA125
expression. In these images, the lymphocytes (stained blue) are seen in typical clusters along the
sides of the node; (E) 20X- and (F) 10X-magnified images of H&E-stained sections of the PETpositive sub-mandibular lymph node; (G) 20X- and (H) 10X-magnified images of the same lymph
node, analyzed by IHC staining for CA125 expression. This node demonstrated gross invasion by
metastatic ovarian cancer cells, which stained positive (dark brown) for the cell surface expression
of CA125.
4.3.2. Near-Infrared Fluorescence Imaging of CA125 Expression in Ovarian Cancer
Cytoreductive surgery with complete gross resection of disease remains the most effective
first-line treatment strategy for patients with advanced ovarian cancer. However, the complete
removal of all malignant tissue can be extremely challenging. The volume of residual disease after
CRS is one of the strongest prognostic indicators for progression free and overall survival. An
intraoperative imaging agent capable of the real-time identification of tumor tissue during surgery
could aid clinicians in the identification and removal of residual disease, thus increasing the volume
of disease resected and improving patient outcomes. This technology would be especially useful
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with regard to clinically normal-appearing lymph nodes for which there is no agreed upon standard
management. We have gathered some preliminary data in the use of and IR800CW-labeled variant
of B43.13 (B43.13-IR800) for the near-infrared fluorescence (NIRF) imaging of CA125 expression
in ovarian cancer.
To evaluate B43.13 antibody for in vitro and in vivo optical imaging, we synthesized more
than one variant of fluorophore-labeled that was utilized for proof-of-concept studies. For example,
we chose to append Alexa Fluor-488 (AF488) for in vitro flow cytometry experiments, whereas
Alexa Fluor-680 (AF680) was chosen for conducting preliminary in vivo fluorescence imaging
studies in relevant xenograft models of high grade serous ovarian cancer. However, since the
ultimate goal of the project was to obtain well-defined fluorophore-labeled-conjugates of the
antibody for potential clinical use, we used a site-specific bioconjugation approach instead of the
traditional approach (Figure 4.6).24-26 While inexpensive and facile, the traditional bioconjugation
method relies on the reaction between the amine-reactive variant of the dye and lysine residues that
are randomly distributed on the surface of the antibody. Due to the lack of site-specificity, this
bioconjugation approach often yields heterogenous immunoconjugates, which could impair the
immunoreactivity of an antibody if the bioconjugation inadvertently occurs in or near the antigenbinding domains.24,

27

To circumvent this potential pitfall, we used a click chemistry-based

chemoenzymatic method developed in our laboratory to site-specifically append the dyes to the
heavy chain glycans of the antibody.24-26, 28-30 Briefly, the methodology is predicated on three steps:
(1) the use of the EndoS enzyme to cleave the heavy chain glycans; (2) the harnessing of a mutant,
promiscuous β-galactosyltransferase [GalT-(Y289L)] to transfer an azide-modified galactose
residue (GalNaz) onto the truncated glycans; and (3) the click ligation between a
dibenzocyclooctyne (DBCO)-modified IR800CW dye and the azide-modified antibody. It has been
demonstrated that this strategy produces more homogenous and well-defined constructs with
89

improved in vivo performance compared to randomly labeled analogues.25, 26, 31-34 Using the sitespecific labeling strategy that would theoretically yield 2 fluorophores per antibody, we were able
to obtain a degree of labeling (DOL) of 1 AF488 dye molecule per B43.13 antibody, whereas a
DOL of 1.5 per B43.13 antibody was obtained with the AF680 dye. In vitro experiments with
CA125-positive OVCAR3 and CA125-negative SKOV3 human ovarian cancer cells clearly
demonstrate that ssB43.13-AF488-EndoS retained the selectivity and affinity of the parent B43.13
antibody for its target antigen (Figure 4.7).

Figure 4.6. Schematic of the chemoenzymatic method for site-specific labeling of the B43.13
antibody. This approach for site-specific labeling of antibodies relies on the modification of the
biantennary glycan chain appended to the asparagine residues at position 297 (N297) on the heavy
chain glycans of immunoglobulin G (IgG) molecules. Briefly, the B43.13 antibody was treated
with a recombinant endoglycosidase (EndoS), which hydrolyses the chitobiose core of the
asparagine-linked glycans to produce a partially deglycosylated antibody. This is followed by
appending an azide-modified sugar (UDP-GalNAz) residue to the partially deglycosylated
antibody using a promiscuous -galactosyltransferase – GalT(Y289L). In the last step, click
chemistry is used to append a dibenzocyclooctene-modified variant of the fluorophore of choice to
the partially deglycosylated and azide modified B43.13 antibody.
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Figure 4.7. In vitro selectivity. FACS data illustrating the selectivity of an AlexaFluor-488-labeled
B43.13 immunoconjugate (B43.13-AF488) using CA125-positive OVCAR3 (left) and CA125negative SKOV3 (right) ovarian cancer cells. Red = unstained cells; Green = blocking condition
created via co-incubation using 2 g/mL B43.13-AF488 and 150 g/mL unlabeled B43.13; Dark
Blue = cells incubated with 1 g/mL B43.13-AF488; Tangerine = cells incubated with 4 g/mL
B43.13-AF488; Turquoise = cells incubated with 8 g/mL B43.13-AF488; Magenta = cells
incubated with 16 g/mL B43.13-AF488. B43.13-AF488-staining of CA125-positive OVCAR3
cells showed a rightward shift of fluorescence from the baseline (unstained OVCAR3 cells) on the
histogram. Blockade of B43.13-AF488-staining by a vast excess of unlabeled B43.13 antibody also
exhibited a lack of a rightward shift in fluorescence – similar to unstained cells. On the other hand,
the histograms for staining CA125-negative SKOV3 cells with similar concentrations of the
B43.13-AF488 showed no shift in fluorescence signal in the histograms suggesting a lack of
antibody binding to this CA125-negative cell line.
Preliminary in vivo NIRF imaging experiments were performed in athymic nude mice
bearing subcutaneous CA125-expressing OVCAR3 human ovarian cancer xenografts (Figure 4.8).
The results from the preliminary studies encouraged us to append a clinically relevant fluorophore
that can be used for NIRF imaging. Thus, IR800CW was adopted as the fluorophore of choice for
site-specific conjugation of the CA125-targeting antibody B43.13 (Figure 4.9). These experiments
revealed that high concentrations of B43.13-IR800 can be seen in the tumor as early as ~24 h after
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the injection of the immunoconjugate. The uptake in the tumor increases with time, ultimately
plateauing around 96-120 hours post-injection (p.i.). Background uptake in the liver was observed
as well, likely due to the formation of immune complexes with CA125 in the blood. Similar to what
was observed previously in previous immunoPET studies (Figures 4.1-4.5) using the CA125targeted B43.13 antibody in subcutaneous OVCAR3 xenografts, and orthotopic ovarian xenografts
uptake of B43.13-IR800 was observed in lymph nodes proximal to the tumor in the NIRF imaging
scans (Figures 4.10-4.11).

Figure 4.8. Near infrared fluorescence (NIRF) in vivo imaging of OVCAR3 subcutaneous
xenograft with B43.13-AF680. Schema outlining the subcutaneous implantation of 106 OVCAR3
cells in immunodeficient mice, which were allowed to grow tumors (200 – 300 mm3) for 5 weeks
before the mice were switched to alfalfa-free low fluorescence diet one week prior to NIRF
imaging. The tumors measured ~300 – 350 mm3 at the time of imaging. Tumors were allowed to
grow slightly larger to allow for potential spread along the ipsilateral lymph node chain as observed
in previous experiments with this model. Longitudinal NIRF imaging after injecting OVCAR3
xenografts with B43.13-AF680 revealed relatively higher intensity fluorescence signal as early as
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D1 after injection of the CA125-targeted NIRF imaging agent. High contrast images were observed
between D3-D7 after injection.

Figure 4.9. Synthesis and in vitro characterization of ssB43.13-IR800 conjugates. (A)
Schematic showing the stepwise synthesis of B43.13 antibody site-specifically labeled with
IR800CW; (B) (L-R) SDS-PAGE carried out under reducing conditions to analyze the shift in the
mobility of immunoglobulin heavy chains of the unmodified B43.13 antibody versus the partially
deglycosylated synthetic intermediate (EndoS-B43.13) resulting from step 1 (shown in A) and the
IR800 click-conjugated EndoS-treated B43.13 antibody (ssB43.13-IR800) resulting from steps 2
and 3 (shown in A); (C) Further resolved SDS-PAGE of the immunoglobulin heavy chains of the
starting material and the intermediates from the immunoconjugate synthesis process as well as the
end-product. A clear downward shift is observed in the EndoS-treated B43.13 due to truncation of
the glycans resulting in a loss of molecular weight (MW). Appending the IR800 dye to the partially
deglycosylated antibody results in a gain in MW leading to an upward shift in mobility of the IgG
heavy chain for ssB43.13-IR800 on SDS-PAGE.
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Figure 4.10. In vivo NIRF imaging with B43.13-IR800. NIRF images of a nude mouse in (A)
prone position and (B) supine position bearing a CA125-positive OVCAR3 xenograft (right flank)
72 h after the administration of B43.13-IR800 (100 g; 0.66 nmol). Note the clear visualization of
the primary tumor as well as the ipsilateral axillary lymph node. (C) NIRF image of the same mouse
with the internal organs exposed, further illustrating the NIRF signal in the tumor and the IALN as
well as the liver. (D) Ex vivo NIRF image illustrating the degree of uptake of B43.13-IR800 in the
tumor (T), ipsilateral axillary lymph nodes (IALN), contralateral axillary lymph nodes (CALN),
ipsilateral inguinal lymph nodes (IILN), contralateral inguinal lymph nodes (CILN), and liver (L).

Figure 4.11. In vivo and ex vivo NIRF imaging of ovarian cancer using IR800-labeled-B43.13.
Bioluminescence image (A) and NIRF image (B) of a mouse, whose left ovary was orthotopically
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xenografted with a CA125-expressing cell line (luciferase-transfected OVCAR3) representative of
human high grade serous ovarian cancer. The mouse was imaged 120 h after the injection of IR800labeled-B43.13 (100 g; 0.66 nmol). Upon necropsy (C), high NIRF signal was observed in the
liver (L) and the left ovary (LO). While the entire liver was fluorescent (D), only the left ovary
(primary tumor) showed high fluorescence in the resected female reproductive tract (E). Resection
of the liver and the female reproductive tract revealed (F) high fluorescence signal in a peritoneal
implant (PI) and renal and lumbar lymph nodes (RLN and LLN). Further resection of the peritoneal
implant (G) allowed better delineation (H) and successful resection (I) of the renal (RLN) and
lumbar lymph nodes (LLN). Finally, all resected tissues including the ipsilateral (IILN) and
contralateral inguinal lymph nodes (CILN) were imaged ex vivo with NIRF as shown in (J).
Histopathological analysis of the resected tissues identified the primary tumor and confirmed the
presence of neoplastic cells bearing characteristics of ovarian adenocarcinoma, thus leading to the
accumulation of IR800-labeled B43.13 in the peritoneal implant (PI), the renal (RLN) and lumbar
lymph nodes (LLN). The inguinal lymph nodes that were negative in the ex vivo NIRF imaging
proved negative upon histopathological analysis for presence of neoplastic cells.
The promising results of the preliminary in vivo experiments prompted us to explore the
use of the highly immunodeficient Nod-Scid-Gamma (NSG) mice to develop subcutaneous,
orthotopic, and patient-derived xenograft (PDX) models of high grade serous ovarian cancer
(HGSOC). We changed the strain of mice from nude to NSG for development of the mouse
xenograft for the following reasons: low take-rate (<25%) of OVCAR3 tumors in nude mice, highly
variable tumor growth – ranging from 4-8 weeks to obtain appropriately sized tumors, and unevenly
sized tumors in <25% of tumor-bearing mice. The use of NSG mice was preferred because the
absence of functional NK cells in this strain allowed for efficient take of the OVCAR3 tumors as
witnessed by ~100% take-rate. Additionally, NSG mice are a preferred strain for propagating
frozen parent PDX tumor seeds to generate larger cohorts of PDX mice for use in preclinical
studies. In these experiments, we added a non-site-specifically modified construct –

nssB43.13-

IR800 – to compare with the site-specifically modified construct – ssB43.13-IR800 and a negative
control –

nssmIgG-IR800

– to validate the specific uptake of ssB43.13-IR800 in CA125-positive

tumors. In NSG mice with subcutaneous OVCAR3 tumors, higher levels of tumoral uptake were
observed with ssB43.13-IR800 (Figure 4.12A) compared to the non-specific uptake of the negative
control, nssmIgGIR800 (Figure 4.12C). This observation was supported by ex vivo imaging, which
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likewise showed higher uptake in the tumor for ssB43.13-IR800 compared to the negative control.
The same trend was observed with ssB43.13-IR800 compared to nssB43.13-IR800 (Figure 4.12B).
In NSG mice with orthotopic OVCAR3 tumors and with PDXs, higher levels of tumoral uptake
were also observed with ssB43.13-IR800 compared to nssB43.13-IR800 and nssmIgG-IR800 (Figure
4.13 and Figure 4.14). Background uptake of ssB43.13-IR800 in the liver was observed as well,
which is consistent with our observations in the nude mice with subcutaneous and orthotopic
OVCAR3 tumors.
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Figure 4.12. In vivo and ex vivo NIRF imaging with ssB43.13-IR800, nssB43.13-IR800, and
ssmIgG-IR800 in an NSG mouse bearing a subcutaneous OVCAR3 xenograft. Representative
NIRF images were obtained in an NSG mouse bearing a CA125-positive OVCAR3 human ovarian
subcutaneous xenograft 72 hours after the intravenous administration of (A) ssB43.13-IR800 (50
µg; 0.33 nmol), (B) nssB43.13-IR800 (50 µg; 0.33 nmol), and (C) nssmIgG-IR800 (50 µg; 0.33
nmol). (Left to right) Representative NIRF images of the live mouse were obtained. Upon necropsy
of the mouse, NIRF images of the harvested tissues and select tissues of interest – tumor (T), liver
(Liv), spleen (Sp), and ovaries (Ov) – were obtained. For the harvested tissues shown above, T =
tumor; H = heart; Lu = lungs; Liv = liver; Sp = spleen; St = stomach; Pa = pancreas; L.I. = large
intestine; S.I. = small intestine; Ov = ovaries; Ki = kidneys; Mu = muscle; Bo = bone.
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Figure 4.13. In vivo and ex vivo NIRF imaging with ssB43.13-IR800, nssB43.13-IR800, and
ssmIgG-IR800 in an NSG mouse bearing an orthotopic OVCAR3 xenograft. Representative
NIRF images were obtained in an NSG mouse bearing a CA125-positive OVCAR3 human ovarian
orthotopic xenograft 72 hours after the intravenous administration of (A) ssB43.13-IR800 (50 µg;
0.33 nmol), (B) nssB43.13-IR800 (50 µg; 0.33 nmol), and (C) nssmIgG-IR800 (50 µg; 0.33 nmol)
(Left to right). Representative NIRF images of the live mouse were obtained. Upon necropsy of the
mouse, NIRF images of the harvested tissues and select tissues of interest – tumor (T), liver (Liv),
spleen (Sp), and ovaries (Ov) – were obtained. For the harvested tissues shown above, T = tumor;
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H = heart; Lu = lungs; Liv = liver; Sp = spleen; St = stomach; Pa = pancreas; L.I. = large intestine;
S.I. = small intestine; Ov = ovaries; Ki = kidneys; Mu = muscle; Bo = bone.

Figure 4.14. In vivo and ex vivo NIRF imaging with ssB43.13-IR800, nssB43.13-IR800, and
nssmIgG-IR800 in an NSG mouse bearing an orthotopic OVCAR3 xenograft. Representative
NIRF images were obtained in an NSG mouse bearing a CA125-positive OVCAR3 human ovarian
orthotopic xenograft 72 hours after the intravenous administration of (A) ssB43.13-IR800 (50 µg;
0.33 nmol) and (B) nssB43.13-IR800 (50 µg; 0.33 nmol). Representative NIRF images of the live
mouse were obtained. Upon necropsy of the mouse, NIRF images of the harvested tissues were
obtained. For the harvested tissues shown above, T = tumor; H = heart; Lu = lungs; Liv = liver; Sp
= spleen; St = stomach; Pa = pancreas; L.I. = large intestine; S.I. = small intestine; Ov = ovaries;
Ki = kidneys; Mu = muscle; Bo = bone.
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Finally, to test the translatability of the IR800-labeled B43.13 antibody, the ssB43.13-IR800
was tested on sections obtained from tumor as well as metastatic lymph node samples harvested
during surgical debulking of high grade serous ovarian patients at Memorial Sloan Kettering
Cancer Center (Figure 4.15). Manual immunohistochemical analysis of adjacent sections of these
tissues with unmodified B43.13 antibody and the ssB43.13-IR800 construct versus a commercially
available anti-CA125 antibody optimized for automated staining on a Ventana instrument revealed
identical staining patterns for CA125 expression using all 3 antibody variants. Importantly, tissues
from patients with CA125-negative tumors (clear cell carcinoma of the ovary) stained negative
with all three antibodies used in this comparative assay. Together, these results suggest minimal if
any loss in the ability of the B43.13 antibody to bind and identify CA125-expressing cells in human
patients – thus making a strong case for clinical translation.
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Figure 4.15. Histopathologic analysis of tumor and lymph node Samples from high grade
serous ovarian cancer patient. Immunohistochemical staining of CA125 – a tumor biomarker for
high-grade serous ovarian cancer – in tumor and lymph node samples obtained from a patient who
underwent surgical debulking to remove peritoneal tumor masses and metastatic lymph nodes. A
high concordance was observed in the staining patterns when equivalent dilutions of unmodified
B43.13, B43.13-IR800, and a commercially available anti-CA125 antibody (Novus Biologicals,
NBP1-96619) were employed for immunohistochemistry. These data clearly demonstrate the
ability of B43.13 to bind human CA125+ HGSOC lesions and underscore that the conjugation of
IR800 to the antibody to create B43.13-IR800 did not impair the immunoconjugate’s ability to bind
CA125-expressing tissues.
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4.4. Conclusion
In this investigation, we have demonstrated that ssB43.13-IR800 can be used to image
CA125-expressing high-grade serous ovarian cancer (HGSOC) tumors in subcutaneous,
orthotopic, and patient-derived xenograft mouse models. In the short term, we believe that the
clinical translation of ssB43.13-IR800 could have a great impact on the health of patients with
HGSOC. A molecularly-targeted imaging agent — such as

ssB43.13-IR800

— capable of

identifying small volume macroscopic or microscopic disease during primary and interval
cytoreductive surgery will facilitate: (a) the accurate assessment of residual disease, (b) the
discrimination between active disease versus radiological (CT/MRI) artifacts due to neoadjuvant
chemo/radiation treatment, and (c) the targeted resection of metastatic abdomino-pelvic lymph
nodes to limit perioperative morbidity such as lower extremity lymphedema by sparing healthy
nodal tissue. Indeed, this technology could push the limits of the surgical treatment of ovarian
cancer beyond the nearly complete ‘gross’ resection of disease.
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Chapter 5 : Conclusions
This work demonstrates how antibodies can be leveraged for positron emission tomography
(PET) and near-infrared fluorescence imaging of breast and ovarian cancers. Taking advantage of
the specificity and affinity of antibodies for its antigen, we were able to explore the effects of a
glycans-based site-specific bioconjugation approach on in vivo performance and develop two
imaging agents for ovarian cancer.
In chapter 2, we investigated how the glycans-based site-specific bioconjugation of
antibodies can impact FcRI binding and in vivo performance. We demonstrated that this approach
results in the attenuation of binding to murine and human FcRI and improves in vivo behavior in
certain immunocompromised mouse models of human breast cancer, particularly the humanized
NSG mouse model. An upcoming clinical trial will help evaluate whether this work is applicable
to human immunoPET.
In chapter 3, we developed the PET imaging agent, [89Zr]Zr-DFO-AR20.5 and evaluated
its in vivo behavior in mice bearing subcutaneous and orthotopic human ovarian cancer xenografts.
Our work clearly demonstrated that [89Zr]Zr-DFO-AR20.5 could be used to clearly delineate the
MUC1-expressing tumor. We plan to explore the use of [89Zr]Zr-DFO-AR20.5 for both diagnostic
and theranostic imaging of ovarian cancer in the future.
In chapter 4, we synthesized the NIRF imaging agent, ssB43.13-IR800 and evaluated its
ability to image CA125-expressing high-grade serous ovarian cancer (HGSOC) tumors in
subcutaneous, orthotopic, and patient-derived xenograft mouse models. Due to its ability to clearly
assess residual disease and delineate lymph nodes and tumor tissue, we believe it has potential for
image-guided surgery in the near future. Taken together, these data indicate the utility of antibodies
for medical imaging applications and clinical potential of our work.
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APPENDICES
CHAPTER 2: APPENDIX
MALDI-ToF spectrum for native pertuzumab (Figure A.2.1)
MALDI-ToF spectrum for DFO-nsspertuzumab (Figure A.2.2)
MALDI-ToF spectrum for N3-sspertuzumab-βGal (Figure A.2.3)
MALDI-ToF spectrum for DFO-sspertuzumab-βGal (Figure A.2.4)
MALDI-ToF spectrum for N3-sspertuzumab-EndoS (Figure A.2.5)
MALDI-ToF spectrum for DFO-sspertuzumab-EndoS (Figure A.2.6)
SDS-PAGE of the immunoconjugates before and after deglycosylation (Figure A.2.7)
Size exclusion chromatogram of native pertuzumab (Figure A.2.8)
Size exclusion chromatogram of DFO-nsspertuzumab (Figure A.2.9)
Size exclusion chromatogram of DFO-sspertuzumab-βGal (Figure A.2.10)
Size exclusion chromatogram of DFO-sspertuzumab-EndoS (Figure A.2.11)
SPR sensorgrams of the binding for recombinant HER2 (Figure A.2.12)
Flow cytometry data with HER2-expressing BT474 cells (Figure A.2.13)
Stability of the three radioimmunoconjugates in human serum (Figure A.2.14)
Degree of labeling of each immunoconjugate as determined via MALDI-MS (Table A.1)
Biodistribution data in nude mice (Table A.2)
Tumor-to-tissue activity concentration ratios in nude mice (Table A.3)
Biodistribution data in humanized NSG mice (Table A.4)
Tumor-to-tissue activity concentration ratios in humanized NSG mice (Table A.5)
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Figure A.2.1. Representative MALDI-ToF spectrum for native pertuzumab.
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Figure A.2.2. Representative MALDI-ToF spectrum for DFO-nsspertuzumab.
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Figure A.2.3. Representative MALDI-ToF spectrum for N3-sspertuzumab-βGal.
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Figure A.2.4. Representative MALDI-ToF spectrum for DFO-sspertuzumab-βGal.
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Figure A.2.5. Representative MALDI-ToF spectrum for N3-sspertuzumab-EndoS.
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Figure A.2.6. Representative MALDI-ToF spectrum for DFO-sspertuzumab-EndoS.
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Figure A.2.7. Denaturing SDS-PAGE of (1/5) unmodified pertuzumab, (2/6) DFO-nsspertuzumab,
(3/7) DFO-sspertuzumab-βGal, and (4/8) DFO-sspertuzumab-EndoS before and after (before/after)
deglycosylation. After deglycosylation, all the heavy glycan chains have the same molecular
weight, except DFO-sspertuzumab-EndoS, because PNGaseF is unable to digest the
immunoconjugate’s truncated glycans. The red dotted line denotes the mass of the heavy chain
glycans of native pertuzumab.
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Figure A.2.8. Size exclusion chromatogram of native pertuzumab

Figure A.2.9. Size exclusion chromatogram of DFO-nsspertuzumab.
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Figure A.2.10. Size exclusion chromatogram of DFO-sspertuzumab-βGal.

Figure A.2.11. Size exclusion chromatogram of DFO-sspertuzumab-EndoS.
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Figure A.2.12. SPR sensorgrams for the binding of (A) native pertuzumab, (B) DFOnsspertuzumab,

(C) DFO-sspertuzumab-EndoS, and (D) DFO-sspertuzumab-βGal for recombinant

HER2.

115

Figure A.2.13. Flow cytometry data showing the binding of the immunoconjugates to HER2expressing BT474 human breast cancer cells.
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Figure A.2.14. Stability of the three radioimmunoconjugates to demetallation in human serum at
37°C. Measurements were analyzed using radio-iTLC and performed in triplicate.
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Constructs

Average mass (Da)

pertuzumab
DFO-nsspertuzumab
N3-sspertuzumab-βGal
DFO-sspertuzumab-βGal
N3-sspertuzumab-EndoS
DFO-sspertuzumab-EndoS

148264 ± 110
149300 ± 185
148645 ± 12
150574 ± 86
147145 ± 59
146998 ± 60

Degree of Labeling
(DFO/mAb)
1.4 ± 0.4
2.6 ± 0.1
1.3 ± 0.2

Table A.2.1. Degree of labeling of each immunoconjugate as determined via MALDI-MS.
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1.68 ± 0.53
0.45 ± 0.18

0.60 ± 0.21
8.42 ± 2.36

41.30 ±
10.54
1.89 ± 0.71
3.06 ± 1.01
4.10 ± 1.19

1.96 ± 0.97
0.63 ± 0.22
0.88 ± 0.42
0.96 ± 0.43
3.56 ± 0.59
0.60 ± 0.14
5.25 ± 3.39

3.15 ± 1.07

45.36 ±
10.54
2.84 ± 1.11
3.65 ± 1.04
3.86 ± 1.76

2.41 ± 1.05
0.77 ± 0.22
1.22 ± 0.51
1.40 ± 0.39
3.52 ± 0.64
0.90 ± 0.32
3.94 ± 3.32

4.44 ± 0.55

30.99 ±
1.84

3.11 ± 0.85

4.40 ± 0.65

3.37 ± 0.50

2.04 ± 0.34

1.35 ± 0.71

1.21 ± 0.19

1.47 ± 0.31

3.74 ± 0.12

0.81 ± 0.41

1.87 ± 0.48

3.73 ± 0.37

Tumor

Heart

Lung

Liver

Spleen

Stomach

SI

LI

Kidney

Muscle

Bone

Skin

4.64 ± 0.59

1.28 ± 0.41

1.08 ± 0.11

3.81 ± 0.35

1.02 ± 0.47

1.11 ± 0.20

0.79 ± 0.35

1.71 ± 0.21

2.51 ± 0.33

4.09 ± 0.55

3.88 ± 0.75

10.41 ±
0.95
31.60 ±
2.10

24 h

4.51 ± 1.97

1.78 ± 0.50

0.76 ± 0.21

4.10 ± 0.90

0.90 ± 0.20

0.98 ± 0.36

0.78 ± 0.44

2.11 ± 0.65

3.56 ± 1.26

3.79 ± 1.53

2.77 ± 1.18

47.88 ± 14.39

8.18 ± 3.29

48 h

4.78 ± 1.58

2.24 ± 0.44

0.84 ± 0.29

5.40 ± 0.54

0.82 ± 0.07

1.03 ± 0.19

0.62 ± 0.16

1.94 ± 0.59

4.92 ± 2.21

4.36 ± 0.88

2.75 ± 0.94

61.05 ±
10.67

7.86 ± 1.36

96 h

5.38 ± 2.56

2.68 ± 0.66

0.71 ± 0.34

5.72 ± 1.21

0.66 ± 0.16

0.63 ± 0.05

0.53 ± 0.15

1.99 ± 0.43

5.22 ± 2.04

3.72 ± 0.97

1.86 ± 0.30

77.15 ±
32.99

5.77 ± 1.53

144 h

89Zr-DFO-sspertuzumab-βGal

3.77 ± 0.66

1.81 ± 0.60

1.08 ± 0.31

3.63 ± 0.41

0.99 ± 0.71

1.13 ± 0.11

0.70 ± 0.27

1.87 ± 0.14

1.96 ± 0.08

4.13 ± 0.65

3.39 ± 0.47

35.60 ±
9.12

9.84 ± 0.84

24 h

5.06 ± 2.37

3.00 ± 0.69

0.91 ± 0.23

4.49 ± 1.16

0.73 ± 0.22

1.03 ± 0.35

0.90 ± 0.31

1.91 ± 0.62

2.43 ± 0.65

4.14 ± 1.61

3.02 ± 1.30

54.64 ±
18.38

8.33 ± 3.31

48 h

3.59 ± 2.50

4.06 ± 1.32

0.51 ± 0.14

4.25 ± 1.24

0.92 ± 0.22

0.78 ± 0.24

0.67 ± 0.38

1.75 ± 0.34

2.47 ± 1.02

3.55 ± 1.10

2.12 ± 0.77

64.43 ±
23.38

6.12 ± 2.11

96 h
4.70 ±
2.12
76.68 ±
28.67
1.78 ±
0.79
2.84 ±
1.21
2.47 ±
1.17
1.77 ±
0.53
0.54 ±
0.27
0.63 ±
0.32
0.48 ±
0.15
4.86 ±
1.57
0.49 ±
0.16
6.50 ±
0.96
4.09 ±
3.00

144 h

89Zr-DFO-sspertuzumab-EndoS

stomach, SI, and LI values include contents.

are %ID/g ± SD; n = 5 mice for each time point and radioimmunoconjugate. SI = small intestine; LI = large intestine. The

Table A.2.2. Biodistribution data for the three constructs in nude mice bearing BT474 subcutaneous xenografts. The values

2.55 ± 0.94

3.47 ± 0.85

0.69 ± 0.15

0.63 ± 0.27

4.50 ± 2.38

2.90 ± 0.98

1.90 ± 0.80

93.15 ±
52.16

4.88 ± 2.09

5.42 ± 2.16

7.17 ± 2.68

9.22 ± 0.72

Blood

144 h

96 h

48 h

24 h

89Zr-DFO-nsspertuzumab
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9.97 ± 2.79

7.05 ± 1.12

9.19 ± 1.48

Heart

Lung

Liver

8.31 ± 0.95

38.25 ±
19.36
16.55 ±
4.32

8.28 ± 0.56

11.06 ± 6.93
36.52 ±
24.46

13.11 ±
5.58

21.84 ±
9.95
13.50 ±
5.65
10.07 ±
3.89
21.05 ±
11.71
66.01 ±
28.60
46.97 ±
25.34
42.93 ±
22.25
11.59 ±
3.53
69.04 ±
24.18

15.95 ±
7.24
12.44 ±
4.56
11.75 ±
6.02
18.79 ±
9.28
58.67 ±
21.81
37.31 ±
17.98
32.33 ±
11.70
12.90 ±
3.80
50.43 ±
21.37
11.51 ±
10.07
10.22 ±
2.70

144 h
19.10 ±
13.47
49.05 ±
34.41
32.14 ±
21.04
20.68 ±
15.94
55.54 ±
35.63
206.49 ±
142.31
147.32 ±
103.77
135.04 ±
81.33
26.84 ±
16.41
156.35 ±
104.07

7.86 ± 5.46

7.62 ± 3.61

96 h

6.32 ± 2.78

48 h

6.81 ± 0.97

29.13 ±
3.64
24.72 ±
8.06

8.30 ± 0.95

12.60 ±
1.85
18.47 ±
2.59
40.16 ±
17.87
28.43 ±
5.54z
31.09 ±
14.45

7.73 ± 1.16

8.14 ± 1.67

3.04 ± 0.34

24 h

17.30 ±
9.02
12.65 ±
6.38
13.46 ±
6.26
22.66 ±
9.77
61.42 ±
39.57
48.68 ±
22.90
52.97 ±
19.72
11.67 ±
4.34
63.04 ±
25.70
26.93 ±
11.11
10.61 ±
5.62

5.86 ± 2.94

48 h

41.58 ±
19.02
20.73 ±
10.39

22.19 ±
8.50
14.01 ±
3.75
12.40 ±
5.98
31.53 ±
11.12
98.09 ±
30.03
59.25 ±
14.88
74.19 ±
14.36
11.30 ±
2.27
72.85 ±
28.14
27.31 ±
7.23
12.78 ±
4.78
9.44 ± 2.93

32.99 ±
12.79
19.71 ±
8.29

14.34 ± 9.18

9.79 ± 2.74

109.22 ±
70.84
28.75 ±
14.17

18.20 ±
4.73
19.08 ±
5.08
51.06 ±
23.73
31.63 ±
8.66
35.97 ±
27.37

8.62 ± 2.59

10.51 ±
3.06

3.62 ± 0.98

24 h

10.79 ± 6.23

18.24 ± 7.42

59.73 ±
24.99

12.16 ± 5.15

28.55 ±
13.29
60.40 ±
29.09
52.87 ±
25.39
74.96 ±
34.16

22.51 ± 9.66

13.20 ± 6.80

18.10 ± 9.88

6.56 ± 3.42

48 h

17.97 ±
14.14

15.86 ± 7.71

126.32 ±
57.76

15.15 ± 7.06

26.05 ±
14.27
36.71 ±
15.14
95.78 ±
64.52
82.89 ±
39.71
70.36 ±
30.47

18.17 ± 8.69

30.43 ±
15.62

10.52 ± 5.27

96 h

18.75 ±
14.03

11.81 ± 4.18

157.71 ±
71.93

15.78 ± 7.06

43.06 ±
24.95
27.04 ±
16.66
31.02 ±
19.78
43.33 ±
24.22
143.29 ±
84.49
120.89 ±
86.03
161.07 ±
94.37

16.31 ± 9.55

144 h

89Zr-DFO-sspertuzumab-EndoS

13.49 ± 6.44

38.71 ±
18.51
146.09 ±
75.09
121.94 ±
53.13
117.47 ±
58.16

14.79 ± 8.58

13.37 ± 6.73

144 h

7.76 ± 1.91

96 h

89Zr-DFO-sspertuzumab-βGal

large intestine. The stomach, SI, and LI values include contents.

xenografts. The values are %ID/g ± SD; n = 5 mice for each time point and radioimmunoconjugate. SI = small intestine; LI =

Table A.2.3. Tumor-to-tissue activity concentration ratios for the three constructs in nude mice bearing BT474 subcutaneous

Skin

Bone

Muscle

Kidney

LI

SI

Stomach

15.17 ±
2.67
22.98 ±
12.14
25.69 ±
4.26
21.15 ±
4.66

3.36 ± 0.33

Blood

Spleen

24 h

Tumor/

89Zr-DFO-nsspertuzumab

89Zr-DFO-

89Zr-DFO-

89Zr-DFO-

nsspertuzumab

sspertuzumab-βGal

sspertuzumab-EndoS

144 h

144 h

144 h

Blood

1.03 ± 0.63

4.51 ± 3.00

8.76 ± 2.31

Tumor

46.13 ± 16.46

77.53 ± 12.56

111.84 ± 39.88

Heart

0.90 ± 0.04

1.76 ± 0.78

2.56 ± 0.23

Lung

2.40 ± 0.50

4.41 ± 1.49

6.55 ± 1.07

Liver

10.25 ± 2.74

8.87 ± 3.53

4.71 ± 0.77

Spleen

44.77 ± 7.92

22.39 ± 17.37

13.09 ± 3.99

Stomach

0.74 ± 0.22

1.08 ± 0.78

0.88 ± 0.25

SI

2.69 ± 0.53

2.44 ± 0.62

1.99 ± 0.49

LI

1.00 ± 0.07

0.92 ± 0.44

1.20 ± 0.73

Kidney

3.94 ± 1.97

5.44 ± 0.65

4.43 ± 0.72

Muscle

0.63 ± 0.17

0.69 ± 0.11

0.90 ± 0.18

Bone

9.14 ± 3.05

5.84 ± 2.11

7.24 ± 2.04

Skin

2.44 ± 0.29

5.34 ± 3.57

4.64 ± 2.20

Table A.2.4. Biodistribution data for the three radioimmunoconjugates at 144 h post-injection in
humanized NSG mice bearing BT474 subcutaneous xenografts. The values are %ID/g ± SD; n =
4 mice for 89Zr-DFO-nsspertuzumab, n = 5 mice for 89Zr-DFO-sspertuzumab-βGal, and n = 5 mice
for 89Zr-DFO-sspertuzumab-EndoS. SI = small intestine; LI = large intestine. The stomach, SI,
and LI values include contents.
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89Zr-DFO-

89Zr-DFO-

89Zr-DFO-

nsspertuzumab

sspertuzumab-βGal

sspertuzumab-EndoS

Tumor/

144 h

144 h

144 h

Blood

44.91± 19.91

17.21 ± 11.78

12.77 ± 5.66

Heart

51.30 ± 18.42

43.95 ± 20.71

43.73 ± 16.08

Lung

19.21 ± 7.93

17.57 ± 6.58

17.09 ± 6.70

Liver

4.50 ± 2.01

8.74 ± 3.75

23.72 ± 9.30

Spleen

1.03 ± 0.41

3.46 ± 2.75

8.54 ± 4.01

Stomach

62.14 ± 28.82

71.89 ± 53.04

127.34 ± 57.69

SI

17.13 ± 6.98

31.84 ± 9.60

56.26 ± 24.41

LI

46.08 ± 16.79

84.15 ± 42.52

93.44 ± 65.84

Kidney

11.72 ± 7.20

14.26 ± 2.87

25.23 ± 9.90

Muscle

73.33 ± 32.53

112.22 ± 25.95

124.41 ± 50.67

Bone

5.05 ± 2.47

13.28 ± 5.27

15.45 ± 7.02

Skin

18.90 ± 7.11

14.53 ± 10.01

24.12 ± 14.33

Table A.2.5. Tumor-to-tissue activity concentration ratios for the three radioimmunoconjugates
at 144 h post-injection in humanized NSG mice bearing BT474 subcutaneous xenografts. The
values are %ID/g ± SD; n = 4 mice for 89Zr-DFO-nsspertuzumab, n = 5 mice for 89Zr-DFOsspertuzumab-βGal,

and n = 5 mice for 89Zr-DFO-sspertuzumab-EndoS. SI = small intestine; LI =

large intestine. The stomach, SI, and LI values include contents.
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CHAPTER 3: APPENDIX
Tumor-to-background activity concentration ratios from nude mice bearing SKOV3 subcutaneous
xenografts (Table A.3.1)
Tumor-to-organ activity concentration ratios from nude mice bearing SKOV3-RFluc orthotopic
xenografts (Table A.3.2)
Biodistribution data for the metastatic lesions collected from nude mice bearing SKOV3-RFluc
orthotopic xenografts (Table A.3.3)
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24 h

72 h

72 h block

120 h

Blood

0.8 ± 0.3

1.9 ± 0.6

0.7 ± 0.3

3.6 ± 1.2

Heart

2.9 ± 1.2

7.1 ± 2.2

2.3 ± 1.0

12.5 ± 4.3

Lungs

1.4 ± 0.6

3.9 ± 1.6

1.3 ± 0.7

7.3 ± 2.5

Liver

1.8 ± 0.8

3.7 ± 1.0

1.2 ± 0.7

5.4 ± 2.0

Spleen

2.7 ± 1.1

4.8 ± 1.9

2.0 ± 1.0

6.9 ± 2.5

Stomach

11.5 ± 5.4

21.9 ± 8.2

8.7 ± 4.4

35.7 ± 14.1

Small Intestine

6.6 ± 2.5

15.7 ± 5.2

6.4 ± 3.0

27.7 ± 9.9

Large Intestine

10.0 ± 3.6

24.8 ± 9.1

9.8 ± 4.4

43.6 ± 18.3

Kidneys

1.8 ± 1.0

4.9 ± 1.6

1.7 ± 0.8

7.5 ± 2.6

Muscle

9.3 ± 3.5

24.6 ± 8.0

7.4 ± 3.5

42.7 ± 14.6

Bone

4.8 ± 1.8

6.1 ± 2.0

2.1 ± 0.9

6.6 ± 3.0

Table A.3.1. Tumor-to-background activity concentration ratios calculated using the
biodistribution data from athymic nude mice (n = 5 per time point) bearing SKOV3 human ovarian
cancer xenografts collected 24, 72, and 120 h after the intravenous administration of [ 89Zr]ZrDFO-AR20.5 (0.65 – 0.69 MBq; 17.6 – 18.6 μCi; 6.6 – 7.0 μg). For the 72 h blocking experiment,
the mice were administered the same amount of [89Zr]Zr-DFO-AR20.5 mixed with a excess of
unmodified AR20.5 (~500 μg per mouse). Stomach, small intestine, and large intestine values
include contents.
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Blood
Heart
Lungs
Liver
Spleen
Stomach
Small Intestine
Large Intestine
Kidneys
Muscle
Bone

[89Zr]Zr-DFO-AR20.5
4.6 ± 4.9
12.9 ± 12.6
7.4 ± 8.0
1.1 ± 0.7
1.9 ± 1.2
33.2 ± 23.5
30.4 ± 19.7
27.5 ± 25.9
5.3 ± 3.5
24.6 ± 19.3
6.6 ± 4.2

[89Zr]Zr-DFO-mIgG
0.7 ± 0.3
2.5 ± 0.8
1.6 ± 0.6
0.6 ± 0.2
0.7 ± 0.3
11.9 ± 5.1
6.5 ± 2.8
6.8 ± 2.4
0.6 ± 0.2
5.1 ± 2.2
1.8 ± 0.6

Table A.3.2. Tumor-to-organ activity concentration ratios derived from the biodistribution data
from athymic nude mice bearing SKOV3-RFluc human ovarian cancer orthotopic xenografts
collected 120 h after the intravenous administration of [89Zr]Zr-DFO-AR20.5 (5.6 – 6.0 MBq;
150.6 – 161.4 μCi; 59.1 – 63.3 μg; n = 3) or [89Zr]Zr-DFO-mIgG (6.1 – 6.4 MBq; 163.7 – 171.7
μCi; 61.5 – 70.1 μg; n = 3) via the tail vein. The stomach, small intestine, and large intestine values
include contents.
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Mouse 1
Mouse 2
Mouse 3

Abdominal Met
Peritoneal Met 1
Peritoneal Met 2
Peritoneal Met
Peritoneal Met
Hepatic Met
Right Ovarian Met 1
Right Ovarian Met 2

[89Zr]Zr-DFO-AR20.5
9.32
6.53
7.44
28.99
5.22
23.02
13.50
5.48

Table A.3.3. Biodistribution data for the metastatic lesions collected from athymic nude mice
bearing SKOV3-RFluc human ovarian cancer orthotopic xenografts 120 h after the intravenous
administration of [89Zr]Zr-DFO-AR20.5 (5.6 – 6.0 MBq; 150.6 – 161.4 μCi; 59.1 – 63.3 μg; n =
3) via the tail vein. The values are %ID/g ± SD; Met = metastatic lesion.
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